Author: "Hospital Universitari Germans Trias I Pujol [Badalona]" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Hospital Universitari Germans Trias I Pujol [Badalona]"' showing total 2,500 results

Start Over Author "Hospital Universitari Germans Trias I Pujol [Badalona]"

2,500 results on '"Hospital Universitari Germans Trias I Pujol [Badalona]"'

1. Avaluació d’intervencions psicològiques en l’àmbit de la violència sexual i física en la infància i l’adolescència

Author: Torres-López, Marta, Mayoral Castany, Agnès, Gálvez Rendón, Carme, Forner Puntonet, Mireia, Llorens Capdevila, Marta, Giralt López, Maria, Fàbregas-Fernández, Anna, Serra-Sutton, Vicky, [Torres M, Serra-Sutton V] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Mayoral A] Hospital Universitari Sant Joan de Déu, Barcelona, Spain. [Gálvez C] Unitat de Pediatria Social, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Forner-Puntonet M] Servei de Salut Mental, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Grup de Psiquiatria, Salut Mental i Addiccions, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain. [Llorens M] Hospital Universitari Sant Joan de Déu, Barcelona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, Spain. [Giralt-López M] Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona, Barcelona, Spain. Servei de Psiquiatria, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Fàbregas A] Servei de Pediatria, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain, and Departament de Salut
Subjects: Maltractament infantil, Social Sciences::Criminology::Crime::Violence::Domestic Violence [ANTHROPOLOGY, EDUCATION, SOCIOLOGY, AND SOCIAL PHENOMENA], Conducta operant - Avaluació, Social Sciences::Criminology::Crime::Sex Offenses [ANTHROPOLOGY, EDUCATION, SOCIOLOGY, AND SOCIAL PHENOMENA], Behavioral Disciplines and Activities::Behavioral Sciences::Psychology [PSYCHIATRY AND PSYCHOLOGY], ciencias sociales::criminología::crimen::violencia::violencia doméstica [ANTROPOLOGÍA, EDUCACIÓN, SOCIOLOGÍA Y FENÓMENOS SOCIALES], disciplinas y actividades conductuales::ciencias de la conducta::psicología [PSIQUIATRÍA Y PSICOLOGÍA], ciencias sociales::criminología::crimen::delitos sexuales [ANTROPOLOGÍA, EDUCACIÓN, SOCIOLOGÍA Y FENÓMENOS SOCIALES], Adolescents - Maltractament
Abstract: Intervencions psicològiques; Violència; Infants; Adolescents Intervenciones psicológicas; Violencia; Infantes; Adolescentes Psychological interventions; Violence; Children; Teenagers En aquest article es presenten avaluacions d'intervencions psicològiques per atendre els infants i adolescents víctimes de violències sexuals i físiques.
Published: 2023

2. Impact of COVID19 pandemic on patients with rare diseases in Spain, with a special focus on inherited metabolic diseases

Author: M.Mar Rovira-Remisa, Mónica Moreira, Paula Sol Ventura, Pablo Gonzalez-Alvarez, Freddzia Graterol-Torres, Clara Joaquín, Agustí Rodríguez-Palmero Seuma, Núria Mestres, Maria del Mar Martínez-Colls, Ana Roche, Salvador Ibáñez, Eduardo López-Laso, María Jesús Méndez-Hernández, Marta Murillo, Laura Monlleó-Neila, Elena Maqueda-Castellote, Mireia del-Toro-Riera, Ana Felipe-Rucián, Maria Giralt-López, Elisenda Cortès-Saladelafont, Institut Català de la Salut, [Rovira-Remisa MM, Mestres N] Unit of Inherited Metabolic Disorders and Pediatric Neurology, Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Moreira M] Department of Psychiatry, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Universitat Autònoma de Barcelona, Campus Can Ruti, Badalona, Spain. [Ventura PS] Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Spain. Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Gonzalez-Alvarez P] Department of Pediatrics, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Graterol Torres F] Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [del Toro Riera M, Felipe-Rucián A] Servei de Neurologia Pediàtrica, Vall d'Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Health Care (Public Health)::Health of Specific Groups::Mental Health [PUBLIC HEALTH], Quality of life, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Rare Diseases [DISEASES], Depression, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Anxiety, COVID-19 (Malaltia), Rare diseases, Nutritional and Metabolic Diseases::Metabolic Diseases [DISEASES], enfermedades nutricionales y metabólicas::enfermedades metabólicas [ENFERMEDADES], afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedades raras [ENFERMEDADES], Endocrinology, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Genetics, Metabolisme, Errors congènits del, Inherited metabolic disease, Malalties rares, Salut mental, Molecular Biology, atención a la salud (salud pública)::salud de grupos específicos::salud mental [SALUD PÚBLICA]
Abstract: Inherited metabolic disease; Quality of life; Rare diseases Enfermedad metabólica hereditaria; Calidad de vida; Enfermedades raras Malaltia metabòlica hereditària; Qualitat de vida; Malalties rares Introduction The Covid-19 pandemic soon became an international health emergency raising concern about its impact not only on physical health but also on quality of life and mental health. Rare diseases are chronically debilitating conditions with challenging patient care needs. We aimed to assess the quality of life and mental health of patients with rare diseases in Spain, with a special focus on inherited metabolic disorders (IMD). Methods A prospective case-control study was designed, comparing 459 patients suffering from a rare disease (including 53 patients with IMD) and 446 healthy controls. Quality of life (QoL) and mental health were assessed using validated scales according to age: KINDL-R and the Pediatric Symptom Checklist (PSC) for children and the WhoQoL-Bref questionnaire, GAD and PHQ-9 in adults. Results First, children and adults (but not adolescents) with IMD showed greater psychological effects than controls (p = 0.022, p = 0.026 respectively). Second, when comparing QoL, only adult patients with IMD showed worse score than controls (66/100 vs 74,6/100 respectively, p = 0.017). Finally, IMD had better quality of life than other rare neurological and genetic diseases (p = 0.008) or other rare diseases (p < 0.001 respectively) but similar alteration of the mental status. Conclusions Our data show that the pandemic had a negative impact on mental health that is more evident in the group of patients with IMD. Young age would behave as a protective factor on the perception of QoL. Furthermore, patients with IMD show a better QoL than other rare diseases.
Published: 2023

3. Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues

Author: Roger Paredes, Marc Noguera-Julian, Lidia Alonso, Roberta Fasani, Alessandra Borgognone, Garazi Serna, Lidia Sanchez, Mariona Parera, Paolo Nuciforo, Francesc Català-Moll, Institut Català de la Salut, [Borgognone A, Parera M, Català-Moll F] IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Serna G, Alonso L, Sanchez L, Fasani R, Nuciforo P] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Noguera-Julian M] IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. Faculty of Medicine, University of Vic–Central University of Catalonia (UVic–UCC), Vic, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Cancer Research, fenómenos microbiológicos::microbiota::microbiota intestinal [FENÓMENOS Y PROCESOS], Recte - Càncer - Aspectes genètics, Firmicutes, microbiome, Còlon - Càncer - Aspectes genètics, colorectal cancer, Computational biology, FFPE, Article, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Intestins - Microbiologia, Microbiome, RC254-282, Microbiological Phenomena::Microbiota::Gastrointestinal Microbiome [PHENOMENA AND PROCESSES], Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics [DISCIPLINES AND OCCUPATIONS], biology, Bacteroidetes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Fusobacteria, 16S gene sequencing, biology.organism_classification, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], Rhodobacterales, Oncology, Fusobacterium, Metagenomics, disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica [DISCIPLINAS Y OCUPACIONES], Bacteroides, RNA in situ hybridization
Abstract: Simple Summary The analysis of colorectal cancer (CRC) gut microbiota can reveal crucial aspects of carcinogenesis and variation of treatment responses. Formalin-fixed, paraffin-embedded (FFPE) tissues represent an invaluable resource for studies in cancer genomics; however, their use in high-throughput metagenomic studies has been questioned due to several limitations in the DNA quality. In this study, we evaluated the impact of sample preservation on CRC-associated microbiota characterization. Using 16S rRNA sequencing and RNA in situ hybridization (RNA-ISH), we found differences in the comparison between paired FFPE and fresh frozen (FF) tissues, mostly derived from contamination issues. A quality index was also outlined to potentially assess the reliability of microbiome profiling obtained from FFPE DNA samples. These results suggest that tissular CRC microbiome studies should preserve internal coherence by using either FFPE or FF samples but not necessarily both. Abstract Formalin-fixed, paraffin-embedded (FFPE) tissues represent the most widely available clinical material to study colorectal cancer (CRC). However, the accuracy and clinical validity of FFPE microbiome profiling in CRC is uncertain. Here, we compared the microbial composition of 10 paired fresh-frozen (FF) and FFPE CRC tissues using 16S rRNA sequencing and RNA-ISH. Both sample types showed different microbial diversity and composition. FF samples were enriched in archaea and representative CRC-associated bacteria, such as Firmicutes, Bacteroidetes and Fusobacteria. Conversely, FFPE samples were mainly enriched in typical contaminants, such as Sphingomonadales and Rhodobacterales. RNA-ISH in FFPE tissues confirmed the presence of CRC-associated bacteria, such as Fusobacterium and Bacteroides, as well as Propionibacterium allowing discrimination between tumor-associated and contaminant taxa. An internal quality index showed that the degree of similarity within sample pairs inversely correlated with the dominance of contaminant taxa. Given the importance of FFPE specimens for larger studies in human cancer genomics, our findings may provide useful indications on potential confounding factors to consider for accurate and reproducible metagenomics analyses.
Published: 2021

4. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness

Author: Julie Bertrand, Marion Kerioui, Aurélien Marc, François Blanquart, Jeremie Guedj, Marc Corbacho-Monné, Oriol Mitjà, Michael Marks, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Université Sorbonne Paris Nord, Centre interdisciplinaire de recherche en biologie (CIRB), Labex MemoLife, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Universitari Germans Trias I Pujol [Badalona], Lihir Medical Centre, International SOS, Londolovit, Papua New Guinea, Hospital Universitari Parc Taulí, Sabadell, Spain, Universitat de Barcelona (UB), London School of Hygiene and Tropical Medicine (LSHTM), Hospital for Tropical Diseases, Oxford University Clinical Research Unit [Ho Chi Minh City] (OUCRU), University College of London [London] (UCL), Université Paris sciences et lettres (PSL)-Collège de France (CdF (institution))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, London School of Hygiene and Tropical Medicine, London, United Kingdom, Hospital for Tropical Diseases, London, United Kingdom, and The study has received financial support from the National Research Agency (ANR) through the ANR-Flash call for COVID-19 (Grant ANR-20-COVI-0018) and the Bill and Melinda Gates Foundation under Grant Agreement INV-017335.
Subjects: Male, viruses, Virus Replication, infectious diseases, 01 natural sciences, law.invention, Cohort Studies, 010104 statistics & probability, 0302 clinical medicine, computational biology, Risk Factors, [MATH.MATH-ST]Mathematics [math]/Statistics [math.ST], law, Biology (General), Prospective cohort study, Microbiology and Infectious Disease, 0303 health sciences, General Neuroscience, [SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE], General Medicine, Middle Aged, Viral Load, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Transmission (mechanics), [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Medicine, Female, epidemiology, Disease transmission, Viral load, Human, Research Article, Adult, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), QH301-705.5, Science, infectious disease, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Biology, General Biochemistry, Genetics and Molecular Biology, Virus, Young Adult, 03 medical and health sciences, Humans, human, Symptom onset, 0101 mathematics, 030304 developmental biology, General Immunology and Microbiology, SARS-CoV-2, microbiology, COVID-19, [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation, Virology, Logistic Models, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Contact Tracing, 030217 neurology & neurosurgery
Abstract: The relationship between SARS-CoV-2 viral load and infectiousness is poorly known. Using data from a cohort of cases and high-risk contacts, we reconstructed viral load at the time of contact and inferred the probability of infection. The effect of viral load was larger in household contacts than in non-household contacts, with a transmission probability as large as 48% when the viral load was greater than 1010 copies per mL. The transmission probability peaked at symptom onset, with a mean probability of transmission of 29%, with large individual variations. The model also projects the effects of variants on disease transmission. Based on the current knowledge that viral load is increased by two- to eightfold with variants of concern and assuming no changes in the pattern of contacts across variants, the model predicts that larger viral load levels could lead to a relative increase in the probability of transmission of 24% to 58% in household contacts, and of 15% to 39% in non-household contacts.
Published: 2021

5. Avaluació d’intervencions psicològiques en l’àmbit de la violència sexual i física en la infància i l’adolescència

Author: Serra-Sutton, Vicky, Torres-López, Marta, Mayoral Castany, Agnès, Gálvez Rendón, Carme, Forner Puntonet, Mireia, Llorens Capdevila, Marta, Giralt López, Maria, Fabregas Martori, Ana, [Serra Sutton V, Torres López M] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain. [Mayoral Castany M, Llorens Capdevila M] Hospital Universitari Sant Joan de Déu de Barcelona, Barcelona, Spain. [Gálvez Rendón C] Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Forner Puntonet, M] Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Giralt López M] Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Departament de Psiquiatria i Medicina Legal, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. [Fàbregas Martori A] Hospital Universitari Vall d’Hebron, Barcelona, Spain. Departament de Pediatria, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain, and Departament de Salut
Subjects: Health Care (Public Health)::Health of Specific Groups::Family Health::Domestic Violence [PUBLIC HEALTH], Maltractament infantil, Conducta operant - Avaluació, Behavioral Disciplines and Activities::Behavioral Sciences::Psychology [PSYCHIATRY AND PSYCHOLOGY], Population Studies in Public Health::Population::Interpersonal Relations::Social Behavior::Social Problems::Crime::Sex Offenses [PUBLIC HEALTH], disciplinas y actividades conductuales::ciencias de la conducta::psicología [PSIQUIATRÍA Y PSICOLOGÍA], Adolescents - Maltractament, atención a la salud (salud pública)::salud de grupos específicos::salud familiar::violencia doméstica [SALUD PÚBLICA], Estudios Poblacionales en Salud Pública::Población::relaciones interpersonales::conducta social::problemas sociales::crimen::delitos sexuales [SALUD PÚBLICA]
Abstract: Intervencions psicològiques; Violència; Infants; Adolescents Psychological interventions; Violence; Infants; Teenagers Intervenciones psicológicas; Violencia; Niños; Adolescentes El maltractament i la violència física o sexual en la infància i l’adolescència són, segons indica l’Organització Mundial de la Salut (OMS), un problema greu de salut pública. També es consideren una violació dels drets humans que pot tenir importants conseqüències per a la salut, el desenvolupament o la dignitat dels infants i adolescents. Així, a les guies i els protocols d’actuació existents es recomana que, davant de símptomes i de l’impacte en la salut mental deguts a la violència, els infants i adolescents rebin suport psicològic. Val a dir que no tots els infants i adolescents que presenten violència física o sexual desenvolupen simptomatologia o trastorns de salut mental. L'objectiu general d'aquest informe és avaluar l’impacte d’una selecció d’intervencions psicològiques en la infància i l’adolescència en el context de la violència física i sexual a partir d’una revisió sistemàtica de l’evidència científica.
Published: 2021

6. Use of IP-10 detection in dried plasma spots for latent tuberculosis infection diagnosis in contacts via mail

Author: Josep Domínguez, Adela Cantos, Esther García-García, J. Ruiz-Manzano, Maria Angeles Jimenez, M. L. De Souza-Galvão, Raquel Villar-Hernández, Morten Ruhwald, Israel Molina-Pinargote, Irene Latorre, Beatriz Muriel-Moreno, J. Pilarte, Cristina Prat, Yoel Gonzalez-Diaz, N. Altet, Joan Pau Millet, Institut Català de la Salut, [Villar-Hernández R, Latorre I] Servei de Microbiología, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Institut d'Investigació Germans Trias i Pujol, Badalona, Spain. CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Badalona, Spain. Universitat Autònoma de Barcelona, Badalona, Spain. [De Souza-Galvão ML, Jiménez MA] Unitat de Tuberculosi Vall d'Hebron-Drassanes, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Ruiz-Manzano J] CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Badalona, Spain. Universitat Autònoma de Barcelona, Badalona, Spain. Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Pilarte J, Cantos A] Unitat de Tuberculosi Vall d'Hebron-Drassanes, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Altet N] Unitat de Tuberculosi Vall d'Hebron-Drassanes, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Unidad Clínica de Tratamiento Directamente Observado 'Serveis Clinics', Barcelona, Spain. CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Badalona, Spain., and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, Adult, Male, Tuberculosis, aminoácidos, péptidos y proteínas::péptidos::péptidos y proteínas de señalización intercelular::citocinas::quimiocinas::quimiocinas CXC::quimiocina CXCL10 [COMPUESTOS QUÍMICOS Y DROGAS], Otros calificadores::/diagnóstico [Otros calificadores], Tuberculosi - Diagnòstic, lcsh:Medicine, Enzyme-Linked Immunosorbent Assay, Sensitivity and Specificity, Article, QuantiFERON, 03 medical and health sciences, 0302 clinical medicine, Latent Tuberculosis, Other subheadings::/diagnosis [Other subheadings], medicine, Humans, Postal Service, Bacterial Infections and Mycoses::Bacterial Infections::Gram-Positive Bacterial Infections::Actinomycetales Infections::Mycobacterium Infections::Tuberculosis::Latent Tuberculosis [DISEASES], lcsh:Science, Whole blood, Multidisciplinary, Chromatography, Latent tuberculosis, Filter paper, Spots, business.industry, infecciones bacterianas y micosis::infecciones bacterianas::infecciones por bacterias grampositivas::infecciones por Actinomycetales::micobacteriosis::tuberculosis::tuberculosis latente [ENFERMEDADES], técnicas de investigación::métodos epidemiológicos::rastreo de contactos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], lcsh:R, Infection diagnosis, Plasma, medicine.disease, Quimiocines, Chemokine CXCL10, 030104 developmental biology, Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines::Chemokines::Chemokines, CXC::Chemokine CXCL10 [CHEMICALS AND DRUGS], ROC Curve, Cytokines, Female, lcsh:Q, Dried Blood Spot Testing, Investigative Techniques::Epidemiologic Methods::Contact Tracing [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Contact Tracing, business, 030217 neurology & neurosurgery, Interferon-gamma Release Tests
Abstract: The aim of this study was to test the use of IP-10 detection in dried plasma from contact studies individuals (contacts of smear positive patients), by comparing it with IP-10 and IFN-γ detection in direct plasma, to establish IP-10 detection in DPS as a useful assay for LTBI diagnosis. Whole blood samples were collected from 80 subjects: 12 with active tuberculosis (TB), and 68 from contact studies. The amount of IFN-γ produced by sensitized T cells was determined in direct plasma by QuantiFERON Gold In-Tube test. IP-10 levels were determined in direct and dried plasma by an in-house ELISA. For dried plasma IP-10 determination, two 25 µl plasma drops were dried in Whatman903 filter paper and sent by mail to the laboratory. Regarding TB patients, 100.0%, 91.7% and 75.0% were positive for IFN-γ detection and IP-10 detection in direct and dried plasma, respectively. In contacts, 69.1%, 60.3% and 48.5% had positive results after IFN-γ and IP-10 in direct and dried plasma, respectively. The agreement among in vitro tests was substantial and IP-10 levels in direct and dried plasma were strongly correlated (r = 0.897). In conclusion, IP-10 detection in dried plasma is a simple and safe method that would help improve LTBI management.
Published: 2019

7. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay

Author: Institut Català de la Salut, [Saludes V] Microbiology Department, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Genetics and Microbiology Department, Universitat Autònoma de Barcelona, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. [Antuori A] Microbiology Department, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Genetics and Microbiology Department, Universitat Autònoma de Barcelona, Badalona, Spain. [Reinhardt B] Abbott GmbH & Co. KG, Wiesbaden, Germany. [Viciana I, Clavijo E] Microbiology Service, Hospital Virgen de la Victoria, Málaga, Spain. [Schreiber L] Maccabi Mega-Lab, Rehovot, Israel. [Rodriguez-Frias F] Laboratori de Patologia Hepatica, Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei de Bioquímica clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Quer J] Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Laboratori de Malalties Hepàtiques, Vall d’Hebron Institut de Recerca, Barcelona, Spain., and Hospital Universitari Vall d'Hebron
Subjects: Viruses::Hepatitis Viruses::Hepacivirus [ORGANISMS], Other subheadings::/methods [Other subheadings], Otros calificadores::Otros calificadores::/genética [Otros calificadores], Otros calificadores::/métodos [Otros calificadores], Técnicas de Investigación::Técnicas Genéticas::Técnicas de Genotipaje [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Investigative Techniques::Genetic Techniques::Genotyping Techniques [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Other subheadings::Other subheadings::/genetics [Other subheadings], Virus de l'hepatitis C - Aspectes genètics, Genètica - Tècnica, Virus::Virus de Hepatitis::Hepacivirus [ORGANISMOS]
Published: 2021

8. Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis

Author: Vallejo Camazon, Nuria, Mateu, Lourdes, Cediel, Germán, Escolà-Vergé, Laura, Fernández-Hidalgo, Nuria, Gurguí, Mercè, Pérez Rodriguez, María Teresa, Cuervo, Guillermo, Núñez Aragón, Raquel, Llibre, Cinta, Sopena, Nieves, Quesada, María Dolores, Berastegui García, Elisabet, Teis, Albert, López Ayerbe, Jorge, Juncà Puig, Gladys, Gual, Francisoc, Ferrer Sistach, Elena, Vivero, Ainhoa, Reynaga, Esteban, Hernández Pérez, María, Muñoz Guijosa, Christian, Pedro-Botet, Lluïsa, Bayés-Genís, Antoni, Universitat Autònoma de Barcelona, Institut Català de la Salut, [Vallejo Camazon N] Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. Department of Medicine, CIBERCV, Autonomous University of Barcelona, Barcelona, Spain. [Mateu L] Unitat Malalties Infeccioses, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Cediel G] Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Escolà-Vergé L, Fernández-Hidalgo N] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gurgui Ferrer M] Unitat de Malalties Infeccioses, Hospital Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, medicine.medical_specialty, Referral, medicine.drug_class, Antibiotics, Bacterial Infections and Mycoses::Bacterial Infections::Endocarditis, Bacterial [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Antibiòtics, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos [COMPUESTOS QUÍMICOS Y DROGAS], Clinical Cardiology, Other subheadings::Other subheadings::/drug therapy [Other subheadings], infecciones bacterianas y micosis::infecciones bacterianas::endocarditis bacteriana [ENFERMEDADES], surgery, Antibiotic therapy, medicine.artery, Ascending aorta, medicine, Medicaments antibacterians - Ús terapèutic, Humans, Endocarditis, In patient, Other subheadings::/therapeutic use [Other subheadings], Aged, Retrospective Studies, Cirurgia, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, infective endocarditis, Endocarditis, Bacterial, General Medicine, Prognosis, medicine.disease, Anti-Bacterial Agents, Surgery, Multicenter study, Infective endocarditis, suppressive antibiotic treatment, Endocarditis bacteriana - Tractament, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [CHEMICALS AND DRUGS], Female, Cardiology and Cardiovascular Medicine, business
Abstract: Edocarditis infecciosa; Tractament antibiòtic supressiu; Cirurgia Endocarditis infecciosa; Tratamiento antibiótico supresor: Cirugía Infective endocarditis; Suppressive antibiotic treatment; Surgery Background: To date, there is little information regarding management of patients with infective endocarditis (IE) that did not undergo an indicated surgery. Therefore, we aimed to evaluate prognosis of these patients treated with a long-term antibiotic treatment strategy, including oral long term suppressive antibiotic treatment in five referral centres with a multidisciplinary endocarditis team. Methods: This retrospective, multicenter study retrieved individual patient-level data from five referral centres in Spain. Among a total of 1797, 32 consecutive patients with IE were examined (median age 72 years; 78% males) who had not undergone an indicated surgery, but received long-term antibiotic treatment (LTAT) and were followed by a multidisciplinary endocarditis team, between 2011 and 2019. Primary outcomes were infection relapse and mortality during follow-up. Results: Among 32 patients, 21 had IE associated with prostheses. Of the latter, 8 had an ascending aorta prosthetic graft. In 24 patients, a switch to long-term oral suppressive antibiotic treatment (LOSAT) was considered. The median duration of LOSAT was 277 days. Four patients experienced a relapse during follow-up. One patient died within 60 days, and 12 patients died between 60 days and 3 years. However, only 4 deaths were related to IE. Conclusions: The present study results suggest that a LTAT strategy, including LOSAT, might be considered for patients with IE that cannot undergo an indicated surgery. After hospitalization, they should be followed by a multidisciplinary endocarditis team. Antoni Bayes-Genis was supported by grants from the Ministerio de Educación y Ciencia (SAF2014–59892), Fundació La MARATÓ de TV3 (201502, 201516), CIBER Cardiovascular (CB16/11/00403), and AdvanceCat 2014. María Hernández Pérez is supported by a Juan Rodes research contract (JR17/00006) from Instituto de Salud Carlos III.
Published: 2021

9. Reliable resolution of ambiguous hepatitis C virus genotype 1 results with the Abbott HCV Genotype Plus RUO assay

Author: B. Reinhardt, Josep Quer, Francisco Rodriguez-Frias, E. Clavijo, I. Viciana, M. Tenenbaum, Lurdes Matas, L. Schreiber, Adrián Antuori, Verónica Saludes, Elisa Martró, Institut Català de la Salut, [Saludes V] Microbiology Department, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Genetics and Microbiology Department, Universitat Autònoma de Barcelona, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. [Antuori A] Microbiology Department, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Genetics and Microbiology Department, Universitat Autònoma de Barcelona, Badalona, Spain. [Reinhardt B] Abbott GmbH & Co. KG, Wiesbaden, Germany. [Viciana I, Clavijo E] Microbiology Service, Hospital Virgen de la Victoria, Málaga, Spain. [Schreiber L] Maccabi Mega-Lab, Rehovot, Israel. [Rodriguez-Frias F] Laboratori de Patologia Hepatica, Servei de Microbiologia, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Servei de Bioquímica clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Quer J] Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Laboratori de Malalties Hepàtiques, Vall d’Hebron Institut de Recerca, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, Viruses::Hepatitis Viruses::Hepacivirus [ORGANISMS], Genotyping Techniques, Other subheadings::/methods [Other subheadings], lcsh:Medicine, Hepacivirus, Viral Nonstructural Proteins, chemistry.chemical_compound, 0302 clinical medicine, Otros calificadores::/métodos [Otros calificadores], Germany, Genotype, Israel, lcsh:Science, Phylogeny, Sanger sequencing, Multidisciplinary, virus::virus de hepatitis::Hepacivirus [ORGANISMOS], Otros calificadores::Otros calificadores::/genética [Otros calificadores], High-Throughput Nucleotide Sequencing, virus diseases, Hepatitis C, Genètica - Tècnica, Subtyping, symbols, Sample collection, técnicas de investigación::técnicas genéticas::técnicas de genotipado [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Concordance, Biology, Real-Time Polymerase Chain Reaction, Article, 03 medical and health sciences, symbols.namesake, Investigative Techniques::Genetic Techniques::Genotyping Techniques [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], medicine, Other subheadings::Other subheadings::/genetics [Other subheadings], Humans, NS5B, Hepatitis, lcsh:R, medicine.disease, Virology, digestive system diseases, 030104 developmental biology, chemistry, Spain, lcsh:Q, Virus de l'hepatitis C - Aspectes genètics, 5' Untranslated Regions, 030217 neurology & neurosurgery
Abstract: Accurate subtyping of hepatitis C virus genotype 1 (HCV-1) remains clinically and epidemiologically relevant. The Abbott HCV Genotype Plus RUO (GT Plus) assay, targeting the core region, was evaluated as a reflex test to resolve ambiguous HCV-1 results in a challenging sample collection. 198 HCV-1 specimens were analysed with GT Plus (38 specimens with and 160 without subtype assigned by the Abbott RealTime Genotype II (GT II) assay targeting the 5’NC and NS5B regions). Sanger sequencing of the core and/or NS5B regions were performed in 127 specimens without subtype assignment by GT II, with “not detected” results by GT Plus, or with mixed genotypes/subtypes. The remaining GT Plus results were compared to LiPA 2.0 (n = 45) or just to GT II results if concordant (n = 26). GT Plus successfully assigned the subtype in 142/160 (88.8%) samples. “Not detected” results indicated other HCV-1 subtypes/genotypes or mismatches in the core region in subtype 1b. The subtyping concordance between GT Plus and either sequencing or LiPA was 98.6% (140/142). Therefore, combined use of GT II and GT Plus assays represents a reliable and simple approach which considerably reduced the number of ambiguous HCV-1 results and enabled a successful subtyping of 98.9% of all HCV-1 samples.
Published: 2019

10. Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes

Author: Marta Hernández, Albert Lecube, Teresa Molí, Carolina López, Jordi Real, Federico Vázquez, Esther Rubinat, Emilio Ortega-Martinez de Victoria, Didac Mauricio, Joan Valls, Minerva Granado-Casas, Núria Alonso, Angels Betriu, Richard David Leslie, Elvira Fernández, [Hernández M, Lecube A] Departament d’Endocrinologia i Nutrició, Hospital Universitari Arnau de Vilanova, Lleida, Spain. Facultat d’Infermeria i Fisioteràpia, Universitat de Lleida, Lleida, Spain. Institut de Recerca Biomèdica de Lleida, Lleida, Spain. [López C] Facultat d’Infermeria i Fisioteràpia, Universitat de Lleida, Lleida, Spain. Institut de Recerca Biomèdica de Lleida, Lleida, Spain. [Real J] Unitat de Suport a la Recerca Lleida, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Lleida, Spain. Epidemiologia i Salut Pública, Universitat International de Catalunya, Sant Cugat del Vallés, Spain. [Valls J] Institut de Recerca Biomèdica de Lleida, Lleida, Spain. Department of Basic Medical Sciences, Universitat de Lleida, Lleida, Spain. [Ortega-Martínez de Victoria E] Departament d’Endocrinologia i Nutrició, CIBEROBN Spanish Biomedical Research Centre in Physiopathology of Obesity, Hospital Clínic, Barcelona, Spain. [Vázquez F, Alonso N] Departament d’Endocrinologia I Nutrició, CIBER of Diabetes and Associated Metabolic Diseases, Health Sciences Research Institute & Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Rubinat E] Facultat d’Infermeria i Fisioteràpia, Universitat de Lleida, Lleida, Spain. [Granado-Casas M] Facultat d’Infermeria i Fisioteràpia, Universitat de Lleida, Lleida, Spain. Department d'Endocrinologia i Nutrició, CIBER of Diabetes and Associated Metabolic Diseases, Health Sciences Research Institute & Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Molí T, Fernández E] UDETMA, Departament de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Betriu A] Institut de Recerca Biomèdica de Lleida, Lleida, Spain. UDETMA, Departament de Nefrologia, Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Leslie RD] The Blizard Institute, Barts and the London School of Medicine and Den tistry, London, UK. [Mauricio-Puente D] Institut de Recerca Biomèdica de Lleida, Lleida, Spain. Departament d’Endocrinologia i Nutrició, CIBER of Diabetes and Associated Metabolic Diseases, Health Sciences Research Institute & Hospital Universitari Germans Trias i Pujol, Badalona, Spain., and IDIAP Jordi Gol
Subjects: Carotid Artery Diseases, Male, lcsh:Diseases of the circulatory (Cardiovascular) system, Endocrinology, Diabetes and Metabolism, Disease, Type 2 diabetes, 030204 cardiovascular system & hematology, LADA, 0302 clinical medicine, enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes autoinmune latente del adulto [ENFERMEDADES], afecciones patológicas, signos y síntomas::afecciones patológicas anatómicas::placa aterosclerótica [ENFERMEDADES], Risk Factors, Original Investigation, Diabetis, Middle Aged, Carotid plaque, Type 1 diabetes, Hypertension, Disease Progression, Female, Cardiology and Cardiovascular Medicine, Late onset autoimmune diabetes, Adult, medicine.medical_specialty, 030209 endocrinology & metabolism, Condiciones Patológicas, Signos y Síntomas::Condiciones Patológicas Anatómicas::Placa Aterosclerótica [ENFERMEDADES], 03 medical and health sciences, Diabetes mellitus, Internal medicine, medicine, Humans, In patient, Pathological Conditions, Signs and Symptoms::Pathological Conditions, Anatomical::Plaque, Atherosclerotic [DISEASES], Latent Autoimmune Diabetes in Adults, Angiology, Aged, Autoantibodies, business.industry, Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Latent Autoimmune Diabetes in Adults [DISEASES], medicine.disease, Atherosclerosis, enfermedades cardiovasculares::enfermedades vasculares::arteriopatías oclusivas::arteriosclerosis::aterosclerosis [ENFERMEDADES], Atheroma, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, lcsh:RC666-701, Autoimmune diabetes, Cardiovascular Diseases::Vascular Diseases::Arterial Occlusive Diseases::Arteriosclerosis::Atherosclerosis [DISEASES], Placa ateroscleròtica, business, Aterosclerosi
Abstract: Atherosclerosis; LADA; Type 1 diabetes; Type 2 diabetes Aterosclerosis; LADA; Diabetes tipo 1; Diabetes tipo 2 Aterosclerosi; LADA; Diabetis tipus 1; Diabetis tipus 2 BACKGROUND LADA is probably the most prevalent form of autoimmune diabetes. Nevertheless, there are few data about cardiovascular disease in this group of patients. The aim of this study was to investigate the frequency of carotid atherosclerotic plaques in patients with LADA as compared with patients with classic type 1 diabetes and type 2 diabetes. METHODS Patients with LADA were matched for age and gender in different proportions to patients with type 2 diabetes, and classic type 1 diabetes. None of the patients had clinical cardiovascular disease. All subjects underwent B-mode carotid ultrasound to detect atheroma plaques. Demographics were obtained from all subjects. RESULTS We included 71 patients with LADA, 191 patients with type 2 diabetes and 116 patients with type 1 diabetes. Carotid atherosclerosis was more frequent in patients with LADA compared with type 2 diabetes (73.2% vs. 56.9%, P = 0.0018) and classic type 1 diabetes (57.1%, P = 0.026); these changes occurred despite healthier macrovascular risk profiles in the former. Age (P < 0.001), smoking (P = 0.003) and hypertension (P = 0.019) were independently associated with carotid atherosclerosis. Multiple plaques were also more frequent in patients with LADA as compared with classic type 1 diabetes and type 2 diabetes (45.1% and 33.6% vs. 27.2%, respectively, P = 0.022). The frequency of carotid plaques increased with increasing diabetes duration in LADA patients compared with type 2 diabetes (85.7% vs. 58.8%, inverse OR 5.72 [1.5-21.8]; P = 0.009). CONCLUSIONS LADA patients do not present with less carotid atherosclerosis than patients with type 1 and type 2 diabetes. Their macrovascular risk occurs despite a healthier macrovascular risk profile than those patients with type 2 diabetes.
Published: 2017

11. Safety and efficacy of 5-aminolevulinic acid for high grade glioma inusual clinical practice: a prospective cohort study

Author: Miguel Ángel Arráez, Xavier Vidal, Juan José Pulido González, Gloria Villalba, Jordi Rimbau, Eva Montané, Pilar Teixidor, Roser Garcia, Manel Tardáguila, [Teixidor,P, Garcia,R, Tardáguila,M, Rimbau,J] Department of Neurosurgery, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Arraez,MA] Department of Neurosurgery, Hospital Carlos Haya, Málaga, Spain. [Villalba,G] Department of Neurosurgery, Hospital del Mar, Barcelona, Spain. [González,JJ] Department of Neurosurgery, Hospital Clínic I Provincial de Barcelona, Barcelona, Spain. [Vidal,X] Fundació Institut Català de Farmacologia, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Vidal,X, Montané,E] Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain. [Montané,E] Department of Clinical Pharmacology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain., and Funding for this work was provided by the Spanish Ministry of Health (through two research projects which codes were: TRA-085 [convocatoria de ayudas para el fomento de la traslación de la aplicación de terapéutica de medicamentos de uso humano, huérfanos y terapias avanzadas de la Orden Ministerial SAS 2481/2009] and EC11-040 [convocatoria de ayudas para la investigación clínica independiente de la Orden Ministerial SPI 2885/2011]).
Subjects: Male, Cervell Tumors, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Keto Acids::Levulinic Acids::Aminolevulinic Acid [Medical Subject Headings], Diagnostic Radiology, Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Glioma [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Medicine, Practice Patterns, Physicians', lcsh:Science, Masculino, Neurological Tumors, 5-Aminolevulinic Acid, Brain Neoplasms, Tumor Resection, Humanos, Oncology, Neurology, 030220 oncology & carcinogenesis, Disease Progression, Health Care::Health Services Administration::Patient Care Management::Delivery of Health Care::Practice Patterns, Physicians' [Medical Subject Headings], Cohort study, medicine.medical_specialty, Drug Research and Development, Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings], Imaging Techniques, Anciano, Estudios de cohortes, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis [Medical Subject Headings], Check Tags::Male [Medical Subject Headings], Surgical and Invasive Medical Procedures, Disease-Free Survival, 03 medical and health sciences, Glioma, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Humans, Clinical significance, Clinical Trials, 5-ALA, Adverse effect, Aged, Pharmacology, Ácido aminolevulínico, Mediana edad, Surgical Resection, lcsh:R, medicine.disease, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Proportional Hazards Models [Medical Subject Headings], Clinical trial, Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies [Medical Subject Headings], lcsh:Q, Clinical Medicine, Probabilidad, 030217 neurology & neurosurgery, Cancer Treatment, lcsh:Medicine, Adulto joven, Cohort Studies, Epidemiology, Medicine and Health Sciences, Prospective cohort study, Multidisciplinary, Patrones de la práctica médica, Adulto, Radiology and Imaging, Femenino, Middle Aged, Modelos de riesgos proporcionales, Magnetic Resonance Imaging, Análisis multifactorial, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability [Medical Subject Headings], Surgical Oncology, Treatment Outcome, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival [Medical Subject Headings], Female, Research Article, Adult, Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms [Medical Subject Headings], Research and Analysis Methods, Young Adult, Diagnostic Medicine, Internal medicine, Progresión de la enfermedad, Sistema nerviós--Cirurgia, Supervivencia sin enfermedad, Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings], Contraindication, Neoplasias cerebrales, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Probability, Proportional Hazards Models, Tumors -- Tractament, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Progression [Medical Subject Headings], business.industry, Cancers and Neoplasms, Aminolevulinic Acid, Surgery, Multivariate Analysis, Resultado del tratamiento, business, Safety Studies
Abstract: BACKGROUND: During the last decade, the use of 5-aminolevulinic acid (5-ALA) has been steadily increasing in neurosurgery. The study's main objectives were to prospectively evaluate the effectiveness and safety of 5-ALA when used in clinical practice setting on high-grade gliomas' patients. METHODS: National, multicenter and prospective observational study. INCLUSION CRITERIA: authorized conditions of use of 5-ALA. EXCLUSION CRITERIA: contraindication to 5-ALA, inoperable or partial resected tumors, pregnancy and children. Epidemiological, clinical, laboratory, radiological, and safety data were collected. Effectiveness was assessed using complete resection of the tumor, and progression-free and overall survival probabilities. RESULTS: Between May 2010 and September 2014, 85 patients treated with 5-ALA were included, and 77 were suitable for the effectiveness analysis. Complete resection was achieved in 41 patients (54%). Surgeons considered suboptimal the fluorescence of 5-ALA in 40% of the patients assessed. The median duration of follow-up was 12.3 months. The progression-free survival probability at 6 months was 58%. The median duration overall survival was 14.2 months. Progression tumor risk factors were grade of glioma, age and resection degree; and death risk factors were grade of glioma and gender. No severe adverse effects were reported. At one month after surgery, new or increased neurological morbidity was 6.5%. Hepatic enzymes were frequently increased within the first month after surgery; however, they subsequently normalized, and this was found to have no clinical significance. CONCLUSION: In clinical practice, the 5-ALA showed a good safety profile, but the benefits related to 5-ALA have not been yet clearly shown. The improved differentiation expected by fluorescence between normal and tumor cerebral tissue was suboptimal in a relevant number of patients; in addition, the expected higher degree of resection was lower than in clinical trials as well as incomplete resection was not identified as a prognostic factor risk for death. Because optimal fluorescence was correlated to higher complete resection rate, further research is needed to identify patients (or tumors) with more surgery benefits when using the 5-ALA. Funding for this work was provided by the Spanish Ministry of Health (through two research projects which codes were: TRA-085 [convocatoria de ayudas para el fomento de la traslación de la aplicación de terapéutica de medicamentos de uso humano, huérfanos y terapias avanzadas de la Orden Ministerial SAS 2481/2009] and EC11-040 [convocatoria de ayudas para la investigación clínica independiente de la Orden Ministerial SPI 2885/ 2011]).
Published: 2016

12. Cirurgia de columna vertebral als hospitals públics de Catalunya: proposta organitzativa

Author: Lafuente, Jesus, Minguell-Moñart, Joan, Torner, Pere, Rimbau Muñoz, Jordi, Cruz Olivé, Enric, Pallisó Folch, Francesc, Nogales López, Julio, Godino Martinez, Oscar, Mateo Olivares, Llorenç, Salo, Guillem, Dominguez Alonso, Carlos, Surís, Xavier, Pozuelo, Alfonso, Casanovas-Guitart, Cristina, Guarga-Rojas, Alejandro, Pons-Vigués, Mariona, [Lafuente Baraza J] Societat Catalana de Neurocirurgia, Barcelona, Spain. [Minguell Moñart J] Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Torner Pifarré P] Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Rimbau Muñoz P, Dominguez Alonso C] Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Cruz Olivé E] Hospital General de Granollers, Granollers, Spain. [Pallisó Folch F] Hospital Universitari Santa Maria de Lleida, Lleida, Societat Catalana de Cirurgia Ortopèdica i Traumatologia (SCCOT), Barcelona, Spain. [Nogales López J] Hospital de Tortosa Verge de la Cinta, Tortosa, Spain. [Godino Martínez O] Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Mateo Olivares Ll] Consorci Sanitari Alt Penedès i Garraf, Vilafranca del Penedès, Spain. [Salo Bru G] Hospital del Mar, Barcelona, Spain. [Surís X, Pozuelo A, Pons M, Casanovas-Guitart C, Guarga A] Àrea Assistencial, Servei Català de la Salut (CatSalut), Departament de Salut, Barcelona, Spain, and Departament de Salut
Subjects: instalaciones, servicios y personal de asistencia sanitaria::centros sanitarios::hospitales::hospitales públicos [ATENCIÓN DE SALUD], Catalonia, Cataluña, sistema musculoesquelético::esqueleto::huesos::columna vertebral [ANATOMÍA], Columna vertebral - Cirurgia, Hospitals públics - Catalunya, Otros calificadores::Otros calificadores::/cirugía [Otros calificadores], Health Care Facilities, Manpower, and Services::Health Facilities::Hospitals::Hospitals, Public [HEALTH CARE], Musculoskeletal System::Skeleton::Bone and Bones::Spine [ANATOMY], Other subheadings::Other subheadings::/surgery [Other subheadings]
Abstract: Cirurgia de columna vertebral; Hospitals públics; Organització Cirugía de columna vertebral; Hospitales públicos; Organización Spinal surgery; Public hospitals; Organization Els objectius d'aques document son: 1. Consensuar els criteris d’indicació de la cirurgia de columna vertebral en diferents situacions clíniques. 2. Analitzar i definir els diferents nivells quirúrgics segons complexitat de la cirurgia de columna vertebral en la població de Catalunya. 3. Establir els criteris i requeriments mínims dels centres hospitalaris per proveir cirurgia de columna vertebral segons els nivells de complexitat a Catalunya.
Published: 2022

13. Determinacions del perfil genètic de tumors sòlids de l’adult

Author: Albanell, Joan, Barnadas, Agustí, Bellosillo, Beatriu, Borras, Josep M., Brunet, Joan, Domènech Maria, Montserrat, Fontanet, Manel, Jares, Pedro, Hernandez-Losa, J., Fernandez, Pedro Luis, Matias-Guiu, Xavier, Molla, Meritxell, Mur, Pilar, Salazar, Ramón, Salud-Salvia, Antonieta, Seguí Palmer, M. A., Tabernero Caturla, Josep, Prat, Aleix, Arriola, Edurne, [Albanell J, Arriola E] Servei d’Oncologia Mèdica, Consorci MAR Parc de Salut de Barcelona, Barcelona, Spain. [Barnadas A] Servei d’Oncologia Mèdica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Bellosillo B] Biologia Molecular, Consorci MAR Parc de Salut de Barcelona, Barcelona, Spain. [Borras JM] Pla director d’oncologia, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Brunet J] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO), Girona, Spain. [Domènech M] Servei d'Oncologia Médica, Hospital Althaia, Manresa, Spain. [Fontanet M] Comissió Farmacoterapèutica del SISCAT, Servei Català de la Salut (CatSalut), Generalitat de Catalunya, Barcelona, Spain. [Jares P] Servei d’Anatomia Patalògica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Hernandez J] Servei d’Anatomia Patològica, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Fernandez PL] Servei d’Anatomia Patològica, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Matias-Guiu X] Servei d’Anatomia Patològica, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Mollà M] Servei d’Oncologia Radioteràpica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Mur P] Programa d’oncologia de precisió, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Prat A] Servei d’Oncologia Mèdica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Salazar R] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO), Generalitat de Catalunya, Hospitalet de Llobregat, Spain. [Salud Salvia A] Servei d’Oncologia Mèdica, Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Segui MA] Servei d’Oncologia Mèdica, Parc Taulí Hospital Universitari, Sabadell, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron Barcelona, Spain, and Departament de Salut
Subjects: Neoplasms [DISEASES], neoplasias [ENFERMEDADES], profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES], Oncologia, Tumors - Aspectes genètics, Otros calificadores::Otros calificadores::/genética [Otros calificadores], Other subheadings::Other subheadings::/genetics [Other subheadings], Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]
Abstract: Perfil genètic; Tumors sòlids; Adults; Precisió Perfil genético; Tumores sólidos; Adultos; Precisión Genetic profile; Solid tumors; Adults; Accuracy En aquest estudi s’ha definit la llista de gens per a cada patologia i tots ells han estat seleccionats atenent a; la seva utilitat diagnòstica per definir els subtipus tumorals en localitzacions tumorals molt concretes; la seva utilitat pronòstica i predictiva, sempre que això comporti un canvi d’actitud terapèutica; la seva utilitat terapèutica per a la indicació de l’ús de fàrmacs diana.
Published: 2022

14. Determinacions del perfil genètic de les malalties neoplàstiques hematològiques

Author: Abrisqueta Costa, Pablo, Bellosillo, Beatriu, Bosch Albareda, Francesc, Briones, Javier, Climent, Fina, Colomer, Dolors, Esteve Reyner, Jordi, Gallardo, David, Garcia Cerecedo, Tomas, Genescà, Eulàlia, Lopez Guillermo, Armando, Nomdedeu, Josep, Pratcorona, Marta, Ribera, Jordi, Ribera, Jose-Maria, Salar, Antonio, Tazon-Vega, Barbara, Valcarcel, David, Zamora, Lurdes, [Abrisqueta P, Bosch F, Tazon B, Valcárcel D] Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Bellosillo B, Salar A] Hospital del Mar, Barcelona, Spain. [Briones J, Nomdedeu J, Pratcorona M] Hospital de la Santa Creu Sant Pau, Barcelona, Spain. [Climent F] Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Colomer D, Esteve J, Lopez A] Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Gallardo D] Institut d’Oncologia Mèdica (ICO), Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain. [Garcia T] Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Genescà E] Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain. [Ribera JM, Zamora L] Institut d’Oncologia Mèdica (ICO), Hospital Universitari Germans Trias i Pujol, Badalona, Spain, and Departament de Salut
Subjects: Hematologia oncològica - Aspectes genètics, profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES], fenómenos genéticos::trasfondo genético::perfil genético [FENÓMENOS Y PROCESOS], Genetic Phenomena::Genetic Background::Genetic Profile [PHENOMENA AND PROCESSES], Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS], profesiones sanitarias::medicina::medicina interna::hematología [DISCIPLINAS Y OCUPACIONES], Tumors, Health Occupations::Medicine::Internal Medicine::Hematology [DISCIPLINES AND OCCUPATIONS]
Abstract: Malalties neoplàstiques hematològiques; Perfil genètic; Precisió Enfermedades neoplásticas hematológicas; Perfil genético; Precisión Hematological neoplastic diseases; Genetic profile; Accuracy La patologia hematooncològica s’ha dividit en tres grups: limfoide, mieloide i leucèmia aguda limfoblàstica. S’ha definit la llista de gens adequada per a cada patologia i tots ells han estat seleccionats atenent a: La seva utilitat diagnòstica i de diagnòstic diferencial amb altres entitats i que, per tant, permetin a l’equip diagnòstic (hematòlegs, patòlegs o biòlegs) realitzar un diagnòstic ben fet. La seva utilitat pronòstica i predictiva, sempre que això comporti un canvi d’actitud terapèutica. Per exemple, indicació de trasplantament de progenitors o altres teràpies cel·lulars, canvi en el seguiment i canvi en el tipus de tractament. La seva utilitat terapèutica per a la indicació de l’ús de fàrmacs diana.
Published: 2022

15. Exploratory study of an oral screening dysplasia program for HIV-infected men who have sex with men

Author: Angela Callejo, Maria del Mar Molina, Maria Carme Dinares, Javier Hernández-Losa, Bibiana Planas, Jorge Garcia, Adria Curran, Jordi Navarro, Paula Suanzes, Vicenç Falcó, Joaquin Burgos, Institut Català de la Salut, [Callejo A] Universitat Autònoma de Barcelona, Bellaterra, Spain. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Department of Otorhinolaryngology. [Del Mar Molina M, Planas B, Garcia J, Curran A, Navarro J, Suanzes P, Falcó V, Burgos J] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Dinares MC, Hernández-Losa J] Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Anatomia Patològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Adult, Male, Anus - Malalties - Epidemiologia, Papillomavirus Infections, Immunology, Anal Canal, HIV Infections, Virus Diseases::Virus Diseases::Sexually Transmitted Diseases::Sexually Transmitted Diseases, Viral::HIV Infections [DISEASES], Anus Neoplasms, Infeccions per VIH - Epidemiologia, Virus Diseases::Virus Diseases::Tumor Virus Infections::Papillomavirus Infections [DISEASES], Sexual and Gender Minorities, Infectious Diseases, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms::Rectal Neoplasms::Anus Neoplasms [DISEASES], Prevalence, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales::neoplasias del recto::neoplasias del ano [ENFERMEDADES], Humans, Immunology and Allergy, virosis::virosis::enfermedades de transmisión sexual::enfermedades virales de transmisión sexual::infecciones por VIH [ENFERMEDADES], Prospective Studies, Homosexuality, Male, virosis::virosis::infecciones por virus oncógenos::infecciones por Papillomavirus [ENFERMEDADES], Papil·lomavirus, Papillomaviridae
Abstract: Dysplasia; Screening; HIV-infected Displasia; Cribado; Infectado por el VIH Displàsia; Cribratge; Infectat pel VIH Background: HIV-infected men who have sex with men (MSM) are at high risk to develop human papilloma virus (HPV)-related oropharyngeal cancer. The aim of our study was to assess the usefulness of a pilot oral dysplasia screening program and its correlation with an anal dysplasia screening program. Methods: This was a prospective study with HIV-infected MSM. Oral and anal screenings were performed based on HPV determination, liquid cytology, direct and microscopy oral examinations, high-resolution anoscopy and biopsies, if necessary. Results: A total of 103 patients were included. The mean age of the patients was 44.6 years, 55.3% were smokers, and 57.3% had a history of previous anal high-grade squamous intraepithelial lesions (HSILs). The prevalence of oral HPV infections was 14% (9% HPV-high risk), the prevalence of abnormal cytology was 25.2%, and in 4.8% of the patients, oral examinations showed suspicious HSILs. Oral microscopy did not detect additional lesions that visual inspection. Five oral biopsies were performed and the results were normal. No risk factors for oral HPV infections were identified. The prevalence of anal HPV infections was 88.3% (76.7% HPV-high risk), 52.9% of the patients had altered cytology, and in 45.6% anoscopy showed changes suggestive of HSILs. Seventy-two anal biopsies were performed, detecting 25 cases of HSILs (24.3%). A poor correlation was observed between oral and anal HPV infections (κ = 0.037). Conclusions: The prevalence of oral HPV infections, abnormal cytology and lesions in HIV-infected MSM was low, and their correlation with anal HPV-related lesions was slight. These results confirm the current barriers to oral dysplasia screening techniques. Study funded by program MISP of MSD (Merck HPV Investigator Study Program). MISP project code 58237.
Published: 2022

16. Combined Approach to Stroke Thrombectomy Using a Novel Short Flexible Aspiration Catheter with a Stent Retriever

Author: Remollo Friedemann, Sebastian, Terceño, Mikel, Werner, Mariano, Castaño, Carlos, Hernández-Pérez, María, Blasco, Jordi, Gimeno, Alfredo, Institut Català de la Salut, [Remollo S, Werner M, Castaño C] Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Interventional Neuroradiology Unit, Badalona, Spain. [Terceño M] Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Interventional Neuroradiology Unit, Badalona, Spain. Stroke Unit, Hospital Universitari Dr. Josep Trueta, Girona, Spain. [Hernández-Pérez M] Stroke Unit, Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Blasco J] Neurointerventional Department C.D.I, Hospital Clinic of Barcelona, Barcelona, Spain. [Gimeno A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Stroke [DISEASES], intervenciones quirúrgicas::procedimientos quirúrgicos cardiovasculares::procedimientos quirúrgicos vasculares::trombectomía [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Surgical Procedures, Operative::Cardiovascular Surgical Procedures::Vascular Surgical Procedures::Thrombectomy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Avaluació de resultats (Assistència sanitària), diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Malalties cerebrovasculars - Cirurgia, Otros calificadores::Otros calificadores::/cirugía [Otros calificadores], cardiovascular diseases, enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos cerebrovasculares::accidente cerebrovascular [ENFERMEDADES], Cateterisme intravascular, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Other subheadings::Other subheadings::/surgery [Other subheadings]
Abstract: Brain ischemia; Mechanical thrombectomy; Device Isquemia cerebral; Trombectomía mecánica; Dispositivo Isquèmia cerebral; Trombectomia mecànica; Dispositiu Background Large-bore aspiration catheters enabling greater flow rates and suction force for mechanical thrombectomy might improve outcomes in patients with stroke secondary to large-vessel occlusion. Complete or near-complete reperfusion after a single thrombectomy pass (first-pass effect) is associated with improved clinical outcomes. We assessed the efficacy and safety of novel MIVI Q™ aspiration catheters in combination with stent-retriever devices. Methods We retrospectively analyzed demographics, procedure characteristics, and clinical data from consecutive patients with acute anterior large-vessel occlusion treated with a combined approach using MIVI Q™ aspiration catheters and stent retrievers. Reperfusion was defined according to the modified thrombolysis in cerebral infarction (mTICI) score. Clinical outcomes were measured by the National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) scores. Results We included 52 patients (median age, 75 y IQR: 64–83); 31 (59.6%) women; 14 (26.9%) with terminal internal carotid artery occlusions, 26 (50%) middle cerebral artery (MCA) segment M1 occlusions, and 12 (23.1%) MCA segment M2 occlusions; median NIHSS score at admission was 19 (IQR: 13–22). After the first pass, 25 (48%) patients had mTICI ≥ 2c. At the end of the procedure, 47 (90.4%) had mTICI ≥ 2b and 35 (67.3%) had mTICI ≥ 2c. No serious device-related adverse events were observed. Symptomatic intracranial hemorrhage developed in 1 patient. Mean NIHSS score was 13 at 24 h and 5 at discharge. At 90 days, 24 (46.2%) patients were functionally independent (mRS 0–2). Conclusion This preliminary study found good efficacy and safety for MIVI Q™ aspiration catheters used in combination with stent-retriever devices.
Published: 2022

17. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Author: Hani Hassoun, Jacob P. Laubach, Jan S. Moreb, Sara Thuresson, Paula Rodriguez-Otero, Marcus Thuresson, Michele Cavo, Albert Oriol, Maria-Victoria Mateos, Joan Bladé, John W. Hiemenz, Adrian Alegre, Amitabha Mazumder, Horizon (Op ) Investigators, Kenneth C. Anderson, Omar Nadeem, Johan Harmenberg, Nicolaas A Bakker, Xavier Leleu, Alessandra Larocca, Christopher Maisel, Paul G. Richardson, Agne Paner, Anastasios Raptis, Cyrille Touzeau, Catriona Byrne, Harvard Medical School [Boston] (HMS), Hospital Universitari Germans Trias I Pujol [Badalona], Università degli studi di Torino = University of Turin (UNITO), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Bologna/Università di Bologna, Clínica Universidad de Navarra [Pamplona], Centre hospitalier universitaire de Poitiers (CHU Poitiers), University of Florida [Gainesville] (UF), Memorial Sloane Kettering Cancer Center [New York], Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Université d'Angers (UA), Université de Nantes (UN), Site de Recherche Intégrée sur le Cancer [Nantes] (SIRIC), Centre hospitalier universitaire de Nantes (CHU Nantes), SIRIC ILIAD [Angers, Nantes], Hospital Universitario Quironsalud, Rush University Medical Center [Chicago], Baylor Scott & White Charles A. Sammons Cancer Center [Dallas, TX, USA], Oncology Institute of Hope and Innovation [Glendale, CA, USA] (OIHI), University of Pittsburgh School of Medicine, Pennsylvania Commonwealth System of Higher Education (PCSHE), Novant Health Forsyth Medical Center [Winston-Salem, NC, USA] (NHFMC), Oncopeptides AB [Stockholm, Sweden], Instituto de Investigación Biomédica de Salamanca [Salamanca, Spain] (IBSAL/CIC), HORIZON (OP-106) Investigators, Bernardo, Elizabeth, Università degli studi di Torino (UNITO), University of Bologna, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Richardson P.G., Oriol A., Larocca A., Blade J., Cavo M., Rodriguez-Otero P., Leleu X., Nadeem O., Hiemenz J.W., Hassoun H., Touzeau C., Alegre A., Paner A., Maisel C., Mazumder A., Raptis A., Moreb J.S., Anderson K.C., Laubach J.P., Thuresson S., Thuresson M., Byrne C., Harmenberg J., Bakker N.A., and Mateos M.-V.
Subjects: Adult, Male, Cancer Research, Time Factors, Time Factor, Phenylalanine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Tumor cells, Drug resistance, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Recurrence, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm, Progression-free survival, Melphalan, Aged, 030304 developmental biology, Aged, 80 and over, 0303 health sciences, Antineoplastic Combined Chemotherapy Protocol, business.industry, Refractory Multiple Myeloma, Middle Aged, medicine.disease, Progression-Free Survival, United States, 3. Good health, Europe, Clinical trial, Oncology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Disease Progression, Cancer research, Female, Multiple Myeloma, business, Human, Conjugate, medicine.drug
Abstract: PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. PATIENTS AND METHODS Patients with RRMM refractory to pomalidomide and/or an anti-CD38 monoclonal antibody received melflufen 40 mg intravenously on day 1 of each 28-day cycle plus once weekly oral dexamethasone at a dose of 40 mg (20 mg in patients older than 75 years). The primary end point was overall response rate (partial response or better) assessed by the investigator and confirmed by independent review. Secondary end points included duration of response, progression-free survival, overall survival, and safety. The primary analysis is complete with long-term follow-up ongoing. RESULTS Of 157 patients (median age 65 years; median five prior lines of therapy) enrolled and treated, 119 patients (76%) had triple-class–refractory disease, 55 (35%) had extramedullary disease, and 92 (59%) were refractory to previous alkylator therapy. The overall response rate was 29% in the all-treated population, with 26% in the triple-class–refractory population. In the all-treated population, median duration of response was 5.5 months, median progression-free survival was 4.2 months, and median overall survival was 11.6 months at a median follow-up of 14 months. Grade ≥ 3 treatment-emergent adverse events occurred in 96% of patients, most commonly neutropenia (79%), thrombocytopenia (76%), and anemia (43%). Pneumonia (10%) was the most common grade 3/4 nonhematologic event. Thrombocytopenia and bleeding (both grade 3/4 but fully reversible) occurred concomitantly in four patients. GI events, reported in 97 patients (62%), were predominantly grade 1/2 (93%); none were grade 4. CONCLUSION Melflufen plus dexamethasone showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated RRMM, including those with triple-class–refractory and extramedullary disease.
Published: 2021

18. Lesiones cerebrales captantes de gadolinio en el brote de los pacientes con esclerosis múltiple

Author: Martin-Aguilar, L, Presas-Rodriguez, S, Rovira, A, Capellades, J, Massuet-Vilamajo, A, Ramio-Torrenta, L, Tintore, M, Brieva-Ruiz, L, Moral, E, Cano-Orgaz, A, Blanco, Y, Batlle-Nadal, J, Carmona, O, Gea, M, Hervas-Garcia, JV, Ramo-Tello, C, Institut Català de la Salut, [Martín-Aguilar L] Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Presas-Rodriguez S] Multiple Sclerosis Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Rovira À] Secció de Neuroradiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Capellades J] Neuroradiology Department, Hospital del Mar, Barcelona, Spain. [Massuet-Vilamajó A] Neuroradiology Section, Diagnostic Imaging Institute, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain. [Ramió-Torrentà L] Multiple Sclerosis Unit, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain. [Tintoré M] Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Brote, Multiple Sclerosis, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Gadolinium, Gadolinium enhancement, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Nervous System::Central Nervous System::Brain [ANATOMY], sistema nervioso::sistema nervioso central::encéfalo [ANATOMÍA], Methylprednisolone, Lesiones captantes de gadolinio, Cervell - Imatgeria per ressonància magnètica, Recurrence, Resonancia magnética, Materials Chemistry, Humans, Relapse, Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings], Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis [DISEASES], Brain, Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores], Magnetic Resonance Imaging, Esclerosis múltiple, enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES], Neurology (clinical), Esclerosi múltiple - Tractament, MRI
Abstract: Esclerosis múltiple; Brote; Resonancia magnética Esclerosi múltiple; Brot; Imatge per ressonància magnètica Multiple sclerosis; Outbreak; Magnetic resonance imaging Objective To study the clinico-radiological paradox in multiple sclerosis (MS) relapse by analyzing the number and location of gadolinium-enhanced (Gd+) lesions on brain MRI before methylprednisolone (MP) treatment. Methods We analyzed brain MRI from 90 relapsed MS patients in two Phase IV multicenter double-blind randomized clinical trials that showed the noninferiority of different routes and doses of MP administration. A 1.5- or 3-T brain MRI was performed at baseline before MP treatment and within 15 days of symptom onset. The number and location of Gd+ lesions were analyzed. Associations were studied using univariate analysis. Results Sixty-two percent of patients had at least 1 Gd+ brain lesion; the median number was 1 (interquartile range 0–4), and 41% of patients had 2 or more lesions. The most frequent location of Gd+ lesions was subcortical (41.4%). Gd+ brain lesions were found in 71.4% of patients with brainstem-cerebellum symptoms, 57.1% with spinal cord symptoms and 55.5% with optic neuritis (ON). Thirty percent of patients with brain symptoms did not have Gd+ lesions, and only 43.6% of patients had symptomatic Gd+ lesions. The univariate analysis showed a negative correlation between age and the number of Gd+ lesions (p = 0.002). Conclusion Most patients with relapse showed several Gd+ lesions on brain MRI, even when the clinical manifestation was outside of the brain. Our findings illustrate the clinico-radiological paradox in MS relapse and support the value of brain MRI in this scenario. Objetivo Estudiar la paradoja clínico-radiológica en el brote de la esclerosis múltiple (EM) mediante el análisis de lesiones captantes de gadolinio (Gd+) en la RM cerebral antes del tratamiento con metilprednisolona (MP). Métodos Analizamos la RM cerebral basal de 90 pacientes con EM en brote de 2 ensayos clínicos aleatorizados multicéntricos fase IV que demostraron la no inferioridad de diferentes vías y dosis de MP, realizadas antes del tratamiento con MP y en los 15 días siguientes a la aparición de los síntomas. Se analizaron el número y la localización de las lesiones Gd+. Se estudiaron las asociaciones mediante análisis univariado. Resultados El 62% de los pacientes tenía al menos una lesión Gd+ cerebral y el 41% de los pacientes tenía 2 o más lesiones. La localización más frecuente fue la subcortical (41,4%). Se encontraron lesiones Gd+ cerebrales en el 71,4% de los pacientes con síntomas de tronco cerebral o cerebelo, en el 57,1% con síntomas medulares y en el 55,5% con neuritis óptica. El 30% de los pacientes con síntomas cerebrales no tenían lesiones Gd+ y sólo el 4,.6% de los pacientes tenían lesiones Gd+ sintomáticas. El análisis univariante mostró una correlación negativa entre la edad y el número de lesiones Gd+ (p = 0,002). Conclusiones La mayoría de los pacientes en brote mostraron varias lesiones Gd+ en la RM cerebral, incluso cuando la manifestación clínica fue medular u óptica. Nuestros hallazgos ilustran la paradoja clínico-radiológica en el brote de la EM y apoyan el valor de la RM cerebral en este escenario. This work was supported in part by the Ministry of Health of Spain (grant numbers EC07/90278 and EC11/132) and personal grant Rio Hortega CM19/00042 to LMA.
Published: 2022

19. Clinical profile and outcome of recurrent infective endocarditis

Author: Rodolfo Citro, Kwan-Leung Chan, Marcelo Haertel Miglioranza, Cécile Laroche, Rossella Maria Benvenga, Shumaila Furnaz, Julien Magne, Carmen Olmos, Bernard P. Paelinck, Agnès Pasquet, Cornelia Piper, Antonio Salsano, Arnaud Savouré, Seung Woo Park, Piotr Szymański, Pierre Tattevin, Nuria Vallejo Camazon, Patrizio Lancellotti, Gilbert Habib, EURO ENDO Investigators Group, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), University of Salerno (UNISA), University of Ottawa [Ottawa], Federal University of Health Sciences of Porto Alegre = Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), European Society of Cardiology (ESC), University of Karachi, Epidémiologie des Maladies Chroniques en zone tropicale (EpiMaCT), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-OmégaHealth (ΩHealth), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Plate forme de bioinformatique et biostatistique (CEBIMER), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Service de cardiologie [CHU Limoges], CHU Limoges, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Antwerp University Hospital [Edegem] (UZA), Université Catholique de Louvain = Catholic University of Louvain (UCL), Ruhr-Universität Bochum [Bochum], Università degli studi di Genova = University of Genoa (UniGe), CHU Rouen, Normandie Université (NU), Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Institute of Cardiology (WARSAW - Cardiology), Institute of Cardiology, CHU Pontchaillou [Rennes], ARN régulateurs bactériens et médecine (BRM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Fight AIDS and Infectious Diseases Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, CHU Sart Tilman [Liege, Belgium], GIGA [Université Liège], Université de Liège, Service de cardiologie Pédiatrique [Marseille], Hôpital de la Timone [CHU - APHM] (TIMONE), Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer AG (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2019), Daiichi Sankyo Europe GmbH (2011–2020), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2016), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2009–2018), Vifor (2019–2022)., Universita degli studi di Genova, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, and UCL - (SLuc) Département cardiovasculaire
Subjects: Male, cardiac surgical procedures, endocarditis, heart valve diseases, Endocarditis, Bacterial, Middle Aged, Staphylococcal Infections, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Recurrence, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Reinfection, Humans, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Hospital Mortality, Human medicine, Cardiology and Cardiovascular Medicine, Retrospective Studies
Abstract: AimsPurpose of this study is to compare the clinical course and outcome of patients with recurrent versus first-episode infective endocarditis (IE).MethodsPatients with recurrent and first-episode IE enrolled in the EUROpean ENDOcarditis (EURO-ENDO) registry including 156 centres were identified and compared using propensity score matching. Recurrent IE was classified as relapse when IE occurred ≤6 months after a previous episode or reinfection when IE occurred >6 months after the prior episode.Results3106 patients were enrolled: 2839 (91.4%) patients with first-episode IE (mean age 59.4 (±18.1); 68.3% male) and 267 (8.6%) patients with recurrent IE (mean age 58.1 (±17.7); 74.9% male). Among patients with recurrent IE, 13.2% were intravenous drug users (IVDUs), 66.4% had a repaired or replaced valve with the tricuspid valve being more frequently involved compared with patients with first-episode IE (20.3% vs 14.1%; p=0.012). In patients with a first episode of IE, the aortic valve was more frequently involved (45.6% vs 39.5%; p=0.061). Recurrent relapse and reinfection were 20.6% and 79.4%, respectively.Staphylococcus aureuswas the microorganism most frequently observed in both groups (p=0.207). There were no differences in in-hospital and post-hospitalisation mortality between recurrent and first-episode IE. In patients with recurrent IE, in-hospital mortality was higher in IVDU patients. Independent predictors of poorer in-hospital and 1-year outcome, including the occurrence of cardiogenic and septic shock, valvular disease severity and failure to undertake surgery when indicated, were similar for recurrent and first-episode IE.ConclusionsIn-hospital and 1-year mortality was similar in patients with recurrent and first-episode IE who shared similar predictors of poor outcome.
Published: 2022

20. Document de consens per a la coinfecció pel Virus de la Immunodeficiència Humana i els Virus de les Hepatitis a Catalunya

Author: Ballesteros, A., Fuster, D., Domingo, Pere, Jaen, Ángeles, Laguno, M., Mallolas, J., Miró, Josep M., Pahissa, Albert, Planas-Vilà, Ramon, Rafecas, Antoni, Ribera, Esteve, Rimola, Antoni, Rufí, G., Sánchez-Tapias, José M., Tural, Cristina, Vargas, Víctor, Xiol, Xavier, [Ballesteros A, Fuster D] Unitat Clínica del VIH, Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Domingo P] Unitat de Malalties Infeccioses, Servei de Medicina Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Jaén A] Centre d’Estudis Epidemiològics sobre la Sida de Catalunya (CEESCAT), Departament de Salut, Badalona, Spain. [Laguno M, Mallolas J, Sánchez-Tapias JM] Serveis d’Infeccions i d’Hepatologia, Hospital Clínic, Barcelona, Spain. [Miró JM] Servei de Malalties Infeccioses, Hospital Clínic, IDIBAPS, Barcelona, Spain. Universitat de Barcelona, IDIBAPS, Barcelona, Spain. [Pahissa A] Servei de Malalties Infeccioses, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Planas-Vilà R] Unitat d’Hepatologia, Servei de l’Aparell Digestiu, Hospital Universitari Germans Trias i Pujol, Badalona, Spain [Rafecas A] Servei de Cirurgia, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain. [Ribera E] Servei de Malalties Infeccioses, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Rimola A] Servei d’Hepatologia, Hospital Clínic, IDIBAPS, Barcelona, Spain. Universitat de Barcelona, IDIBAPS, Barcelona, Spain. [Rufí G] Servei de Malalties Infeccioses, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain. [Tural C] Unitat Clínica del VIH, Servei de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Vargas V] Servei d’Hepatologia, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Xiol X] Servei de l’Aparell Digestiu, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, and Departament de Salut
Subjects: Virus Diseases::Coinfection [DISEASES], virosis::virosis::enfermedades de transmisión sexual::enfermedades virales de transmisión sexual::infecciones por VIH [ENFERMEDADES], virosis::coinfección [ENFERMEDADES], Other subheadings::/diagnosis [Other subheadings], Otros calificadores::/diagnóstico [Otros calificadores], Hepatitis vírica - Tractament, Hepatitis vírica - Diagnòstic, Virus Diseases::Virus Diseases::Sexually Transmitted Diseases::Sexually Transmitted Diseases, Viral::HIV Infections [DISEASES], Environmental Health::Health::Environmental Illness::Virus Diseases::Hepatitis [PUBLIC HEALTH], Infeccions per VIH - Tractament, salud ambiental::salud::enfermedad ambiental::virosis::hepatitis [SALUD PÚBLICA]
Abstract: VIH; Virus de les Hepatitis; Coinfecció VIH; Virus de las Hepatitis; Coinfección HIV; Hepatitis virus; Coinfection Aquest manual ha estat preparat amb la intenció d'abordar els problemes que planteja el maneig de les persones malaltes amb coinfecció pel virus de la sida i els virus de l'hepatitis. A més, facilita als metges i metgesses assistencials els recursos necessaris per al diagnòstic i la presa de decisions terapèutiques, així com els criteris per ampliar la prevenció en tots aquells grups de població exposats a contraure aquestes infeccions. Este manual ha sido preparado con la intención de abordar los problemas que plantea el manejo de las personas enfermas con coinfección por el virus del sida y los virus de la hepatitis. Además, facilita a los médicos asistenciales los recursos necesarios para el diagnóstico y la toma de decisiones terapéuticas, así como los criterios para ampliar la prevención en todos aquellos grupos de población expuestos a contraer estas infecciones.
Published: 2005

21. An interventional nationwide surveillance program lowers postoperative infection rates in elective colorectal surgery. A cohort study (2008-2019)

Author: Arroyo-García, Nares, Badia, Josep M., Vázquez, Ana, Pera Roman, Miguel, Parés, David, Limón, Enric, Almendral, Alexander, Piriz, Marta, Cecilia, Díez, Fraccalvieri, Domenico, López Contreras, Joaquín, Pujol, Miquel, Colorectal Surveillance Team, VINCat Program, Arroyo-García, Nares, Badia, Josep M., Vázquez, Ana, Pera Roman, Miguel, Parés, David, Limón, Enric, Almendral, Alexander, Piriz, Marta, Cecilia, Díez, Fraccalvieri, Domenico, López Contreras, Joaquín Pujol, Miquel, Colorectal Surveillance Team, VINCat Program, [Arroyo-Garcia N, Badia JM] Department of Surgery, Hospital General Granollers, Granollers, Spain. School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. [Vázquez A] Servei d’Estadística Aplicada, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Pera M] Department of Surgery, Hospital del Mar, Barcelona, Spain. [Parés D] Department of Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Limón E] VINCat Program, Universitat de Barcelona, Barcelona, Spain, and Hospital General de Granollers
Subjects: Prevenció i control, Infeccions quirúrgiques, Cirurgia colorectal, Surgical wound infection, Estudios de cohortes, Infection control, Còlon - Cirurgia, Cohort Studies, Health Occupations::Medicine::Specialties, Surgical::Colorectal Surgery [DISCIPLINES AND OCCUPATIONS], Cirugía colorrectal, Control d'infeccions, Prevención y control, Colorectal surgery, Risk Factors, Infección del sitio quirúrgico, Humans, Surgical Wound Infection, Estudis de cohorts, Epidemiologia, Proporción de infección estandarizada, Digestive System Surgical Procedures, Standardized infection ratio, Infecció del lloc quirúrgic, Adverse effects, Prevention & control, Infeccions quirúrgiques - Estudi de casos, Cirurgia colorrectal, General Medicine, Efectos adversos, Infección de la herida quirúrgica, Elective Surgical Procedures, profesiones sanitarias::medicina::especialidades quirúrgicas::cirugía colorrectal [DISCIPLINAS Y OCUPACIONES], Ratio d'infecció estandarditzat, Surgery, Efectes adversos, Colorectal Surgery, Surgical site infection, Infecció de ferides quirúrgiques
Abstract: Colorectal surgery; Postoperative infection; Cohort studies Cirugía colorrectal; Infección postoperatoria; Estudios de cohortes Cirurgia colorectal; Infecció postoperatòria; Estudis de cohorts Background: Colorectal surgery is associated with the highest rate of surgical site infection (SSI). This study analyses the effectiveness of an interventional surveillance program on SSI rates after elective colorectal surgery. Material and methods: Cohort study showing temporal trends of SSI rates and Standardized Infection Ratio (SIR) in elective colorectal surgery over a 12-year period. Prospectively collected data of a national SSI surveillance program was analysed and the effect of specific interventions was evaluated. Patient and procedure characteristics, as well as SIR and SSI rates were stratified by risk categories and type of SSI analysed using stepwise multivariate logistic regression models. Results: In a cohort of 42,330 operations, overall cumulative SSI incidence was 16.31%, and organ-space SSI (O/S-SSI) was 8.59%. There was a 61.63% relative decrease in SSI rates (rho = -0.95804). The intervention which achieved the greatest SSI reduction was a bundle of 6 measures. SSI in pre-bundle period was 19.73% vs. 11.10% in post-bundle period (OR 1.969; IC 95% 1.860-2.085; p < 0.0001). O/S-SSI were 9.08% vs. 6.06%, respectively (OR 1.547; IC 95% 1.433-1.670; p < 0.0001). Median length of stay was 7 days, with a significant decrease over the studied period (rho = -0.98414). Mortality of the series was 1.08%, ranging from 0.35% to 2.0%, but a highly significant decrease was observed (rho = -0.67133). Conclusions: Detailed analysis of risk factors and postoperative infection in colorectal surgery allows strategies for reducing SSI incidence to be designed. An interventional surveillance program has been effective in decreasing SIR and SSI rates.
Published: 2021

22. Higher mortality and intubation rate in COVID-19 patients treated with noninvasive ventilation compared with high-flow oxygen or CPAP

Author: Marti, Sergi, Carsin, Anne-Elie, Sampol, Júlia, Pallero, Mercedes, Aldas Criado, Irene, Marin, Toni, Luján, Manel, Lalmolda, Cristina, Sabater, Gladis, Bonnin-Vilaplana, Marc, Peñacoba, Patricia, Martinez-Llorens, Juana, Tárrega, Julia, Bernadich, Óscar, Córdoba-Izquierdo, Ana, Lozano, Lourdes, Mendez, Susana, Vélez-Segovia, Eduardo, Prina, Elena, Eizaguirre, Saioa, Balañá Corberó, Ana, Ferrer Sancho, Jaume, Garcia-Aymerich, J., Universitat Autònoma de Barcelona, [Marti S, Sampol J, Pallero M, Ferrer J] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain. [Carsin AE] ISGlobal, Barcelona, Spain. Universitat Pompeu Fabra (UPF), Barcelona, Spain. CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Aldas I, Marin T] Respiratory Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Tárrega J] Respiratory Department, Hospital General de Granollers, Granollers, Spain. Universitat Internacional de Catalunya, Barcelona, Spain. [Vélez Segovia E] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Hospital General de Granollers
Subjects: Multidisciplinary, Noninvasive Ventilation, Respiratory distress syndrome, Continuous Positive Airway Pressure, Therapeutics::Airway Management::Intubation, Intratracheal [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], terapéutica::manejo de la via aérea::respiración artificial::ventilación no invasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], COVID-19, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Terapèutica, COVID-19 (Malaltia), Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections::Severe Acute Respiratory Syndrome [DISEASES], Oxygen, terapéutica::manejo de la via aérea::intubación endotraqueal [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Insuficiència respiratòria, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus::síndrome respiratorio agudo grave [ENFERMEDADES], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Intubation, Intratracheal, Infectious diseases, Humans, Therapeutics::Airway Management::Respiration, Artificial::Noninvasive Ventilation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Respiratory insufficiency, Respiratory Insufficiency
Abstract: COVID-19; Noninvasive ventilation; High-flow oxygen COVID-19; Ventilación no invasiva; Oxígeno de alto flujo COVID-19; Ventilació no invasiva; Oxigen d'alt cabal The effectiveness of noninvasive respiratory support in severe COVID-19 patients is still controversial. We aimed to compare the outcome of patients with COVID-19 pneumonia and hypoxemic respiratory failure treated with high-flow oxygen administered via nasal cannula (HFNC), continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV), initiated outside the intensive care unit (ICU) in 10 university hospitals in Catalonia, Spain. We recruited 367 consecutive patients aged ≥ 18 years who were treated with HFNC (155, 42.2%), CPAP (133, 36.2%) or NIV (79, 21.5%). The main outcome was intubation or death at 28 days after respiratory support initiation. After adjusting for relevant covariates and taking patients treated with HFNC as reference, treatment with NIV showed a higher risk of intubation or death (hazard ratio 2.01; 95% confidence interval 1.32-3.08), while treatment with CPAP did not show differences (0.97; 0.63-1.50). In the context of the pandemic and outside the intensive care unit setting, noninvasive ventilation for the treatment of moderate to severe hypoxemic acute respiratory failure secondary to COVID-19 resulted in higher mortality or intubation rate at 28 days than high-flow oxygen or CPAP. This finding may help physicians to choose the best noninvasive respiratory support treatment in these patients.Clinicaltrials.gov identifier: NCT04668196.
Published: 2021

23. Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study

Author: Elena Palà, Alejandro Bustamante, Josep Lluis Clúa-Espuny, Juan Acosta, Felipe González-Loyola, Sara Dos Santos, Domingo Ribas-Segui, Juan Ballesta-Ors, Anna Penalba, Marina Giralt, Iñigo Lechuga-Duran, Delicia Gentille-Lorente, Alonso Pedrote, Miguel Ángel Muñoz, Joan Montaner, Fundació La Marató de TV3, Vall d'Hebron Research Institute, European Commission, Institut Català de la Salut, [Palà E, Penalba A] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bustamante A] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Stroke Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Clúa-Espuny JL] Equip d’Atenció Primària Tortosa Est, SAP Terres de l’Ebre, Institut Català de la Salut, Tortosa, Spain. Institut d’Investigació en Atenció Primària IDIAP Jordi Gol, Unitat de Suport a la Recerca de Barcelona, Barcelona, Spain. [Acosta J] Department of cardiology, Hospital Universitario Virgen del Rocio, Sevilla, Spain. [González-Loyola F] Institut d’Investigació en Atenció Primària IDIAP Jordi Gol, Unitat de Suport a la Recerca de Barcelona, Barcelona, Spain. Gerència Atenció Primària de Barcelona, Institut Català de la Salut, Barcelona, Spain. [Dos Santos S] CAP Horta 7F, Àmbit d’Atenció Primària Barcelona ciutat, Institut Català de la Salut, Barcelona, Spain. [Giralt M] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Montaner J] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Institute de Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/ CSIC/University of Seville & Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Cardiovascular::Heart Function Tests::Electrocardiography::Electrocardiography, Ambulatory [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Multidisciplinary, enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial [ENFERMEDADES], Biological Factors::Biomarkers [CHEMICALS AND DRUGS], factores biológicos::biomarcadores [COMPUESTOS QUÍMICOS Y DROGAS], Electrocardiografia, Spain, Marcadors bioquímics, diagnóstico::técnicas y procedimientos diagnósticos::técnicas diagnósticas cardiovasculares::pruebas de función cardíaca::electrocardiografía::electrocardiografía ambulatoria [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Atrial Fibrillation, Fibril·lació auricular, Electrocardiography, Ambulatory, Humans, Prospective Studies, Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Atrial Fibrillation [DISEASES], Biomarkers
Abstract: [Background and objective] AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring., [Methods] 359 subjects aged 65–75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (NuuboTM), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck., [Results] AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p, [Conclusion] The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible., This work was supported by Fundació Marató de TV3 in the research call “La Marató 2014: malalties del cor” [grant number: 201528-30-31-3]. EP received a predoctoral grant from Vall d’Hebron Institute of Research. Neurovascular Research Laboratory also takes part in the Span-ish stroke research network INVICTUS+ [RD16/0019]. This project is supported by AFFECT-EU, receiving funding from the European Union’s Horizon 2020 research and innovation pro-gramme under grant agreement N°847770.
Published: 2021

24. Mesures excepcionals d’optimització i alternatives als EPI en situació d’emergència de COVID-19

Author: Armadans Gil, Lluis, Artigas Lage, Montse, Calvet Tort, Gemma, Campins Martí, Magda, Casas-García, Irma, Castellà-Fàbregas, Laia, Domènech-Bagué, Dolors, Domenech-Spanedda, Marie France, Gavaldà Mestre, Laura, Gutiérrez-Milla, Carme, [Artigas-Lage M, Calvet-Tort G] Direcció de Cures, Centre Corporatiu, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Campins-Martí M] Hospital Universitari Vall d’Hebron, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain. [Castellà-Fàbregas L] Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut (ICS), Generalitat de Catalunya, Badalona, Spain. [Domènech-Bagué D] Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Girona, Spain. [Domènec-Spanedda MF] Hospital de Tortosa Verge de la Cinta, Institut Català de la Salut (ICS), Generalitat de Catalunya, Tortosa, Spain. [Gavaldà-Mestre L, Gutiérrez-Milla C] Hospital Universitari de Bellvitge, Institut Català de la Salut (ICS), Generalitat de Catalunya, L’Hospitalet de Llobregat, Spain, Departament de Salut, [Armadans Gil L, Campins Martí M] Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Artigas Lage M, Calvet Tort G] Direcció de Cures, Institut Català de la Salut (ICS), Barcelona, Spain. [Casas García I, Castellà Fàbregas L] Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Domènech Bagué D] Servei de Medicina Preventiva, Hospital Universitari Doctor Josep Trueta, Girona, Spain. [Domènech Spanedda MF] Hospital de Tortosa Verge de la Cinta, Tortosa, Spain. [Gavaldà Mestre L, Gutiérrez Milla C] Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, and Institut Català de la Salut
Subjects: Other subheadings::Other subheadings::/prevention & control [Other subheadings], Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores], Roba de protecció, COVID-19 (Malaltia) - Prevenció, Equipment and Supplies::Protective Devices::Protective Clothing [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Infections::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Coronavirus - Prevenció, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Equipos y Suministros::Equipos de Seguridad::Ropa de Protección [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], COVID-19 (Malaltia), equipos y suministros::equipos de protección::vestuario de protección [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Infeccions per coronavirus
Abstract: Equips de protecció individual; EPI; Mesures d'optimització; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Equipos de protección individual; EPI; Medidas de optimización; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV Personal protective equipment; EPI; Optimization measures; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV El propòsit d’aquest document és recomanar accions per a l’optimització dels equips de protecció individual (EPI), segures per als professionals i els pacients, en el context present de pandèmia per la COVID-19 i per actuar davant de possibles desabastiments d’aquests equipaments.
Published: 2021

25. Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections

Author: Faura, J, Bustamante, A, Miro-Mur, F, Montaner, J, [Faura,J, Montaner,J] Neurovascular Research Laboratory, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain. [Bustamante,A] Stroke Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Miró-Mur,F] Systemic Autoimmune Research Unit, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain. [Montaner,J] Stroke Research Program, Institute of Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville & Department of Neurology, Hospital Universitario Virgen de la Macarena, Seville, Spain., and This project received funding from Instituto de Salud Carlos III (ISCIII) [PI17/02130], co-financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706]. Neurovascular Research La boratory takes part into the Spanish stroke research network INVICTUS+[RD16/0019/0021].
Subjects: Inflammation, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines [Medical Subject Headings], Infecciones, Inflamación, Anatomy::Hemic and Immune Systems::Blood::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes [Medical Subject Headings], Pneumonia, Diseases::Respiratory Tract Diseases::Respiratory Tract Infections::Pneumonia [Medical Subject Headings], Anatomy::Respiratory System::Lung [Medical Subject Headings], Accidente cerebrovascular, Anatomy::Hemic and Immune Systems::Immune System::Phagocytes::Neutrophils [Medical Subject Headings], Terapia de inmunosupresión, Stroke, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Anatomy::Cells::Phagocytes::Monocytes [Medical Subject Headings], Biomarcadores, Diseases::Bacterial Infections and Mycoses::Infection [Medical Subject Headings], Neumonía, Organisms::Eukaryota::Animals [Medical Subject Headings], Diseases::Cardiovascular Diseases::Vascular Diseases::Cerebrovascular Disorders::Stroke [Medical Subject Headings], Infection, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings], Immunosuppression, Biomarkers
Abstract: Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and beta -blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid.
Published: 2021

26. Determinacions del perfil genètic de tumors sòlids de l’adult

Author: Albanell, Joan, Barnadas, Agustí, Bellosillo, Beatriu, Borras, Josep M., Domènech Maria, Montserrat, Fontanet, Manel, Jares, Pedro, Hernandez-Losa J., Fernandez, Pedro Luis, Matias-Guiu, Xavier, Molla, Meritxell, Prat, Aleix, Salazar, Ramón, Salud-Salvia, Antonieta, Seguí Palmer, M. A., Tabernero Caturla, Josep, [Albanell J] Servei d’Oncologia Mèdica, Consorci MAR Parc de Salut de Barcelona, Barcelona, Spain. [Barnadas A] Servei d’Oncologia Mèdica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Bellosillo B] Biologia Molecular, Consorci MAR Parc de Salut de Barcelona, Barcelona, Spain. [Borras JM] Pla director d’oncologia, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Domènech M] Servei d'Oncologia Médica, Hospital Althaia, Manresa, Spain. [Fontanet M] Comissió Farmacoterapèutica del SISCAT, Servei Català de la Salut (CatSalut), Generalitat de Catalunya, Barcelona, Spain. [Jares P] Servei d’Anatomia Patalògica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Hernandez J] Servei d’Anatomia Patològica, Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Fernandez PL] Servei d’Anatomia Patològica, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Matias-Guiu X] Servei d’Anatomia Patològica, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Mollà M] Servei d’Oncologia Radioteràpica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Prat A] Servei d’Oncologia Mèdica, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. [Salazar R] Servei d’Oncologia Mèdica, Institut Català d’Oncologia (ICO), Generalitat de Catalunya, Hospitalet de Llobregat, Spain. [Salud Salvia A] Servei d’Oncologia Mèdica, Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Segui MA] Servei d’Oncologia Mèdica, Parc Taulí Hospital Universitari, Sabadell, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Hospital Universitari Vall d’Hebron Barcelona, Spain, and Departament de Salut
Subjects: Neoplasms [DISEASES], neoplasias [ENFERMEDADES], profesiones sanitarias::medicina::medicina interna::oncología médica [DISCIPLINAS Y OCUPACIONES], Oncologia, Tumors - Aspectes genètics, Otros calificadores::Otros calificadores::/genética [Otros calificadores], Other subheadings::Other subheadings::/genetics [Other subheadings], Health Occupations::Medicine::Internal Medicine::Medical Oncology [DISCIPLINES AND OCCUPATIONS]
Abstract: Perfil genètic; Tumors sòlids; Adults; Precisió Perfil genético; Tumores sólidos; Adultos; Precisión Genetic profile; Solid tumors; Adults; Accuracy En aquest estudi s’ha definit la llista de gens per a cada patologia i tots ells han estat seleccionats atenent a; la seva utilitat diagnòstica per definir els subtipus tumorals en localitzacions tumorals molt concretes; la seva utilitat pronòstica i predictiva, sempre que això comporti un canvi d’actitud terapèutica; la seva utilitat terapèutica per a la indicació de l’ús de fàrmacs diana.
Published: 2021

27. Native α-Synuclein, 3-Nitrotyrosine Proteins, and Patterns of Nitro-α-Synuclein-Immunoreactive Inclusions in Saliva and Submandibulary Gland in Parkinson’s Disease

Author: Fernando Rodríguez de Fonseca, Emilio Fernández-Espejo, Joan Berenguer, Juan Suárez, Dolores Vilas, Iban Aldecoa, Eduardo Tolosa, Fátima Damas-Hermoso, [Fernández-Espejo,E] Reial Acadèmia de Medicina de Catalunya, Barcelona, Spain. [Fernández-Espejo,E] Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA), Laboratorio de Medicina Regenerativa, Hospital Regional Universitario, Málaga, Spain. [Rodríguez de Fonseca,F] Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario, Málaga, Spain. [Suárez,J] Departamento de Anatomía Humana, Medicina Legal e Historia de la Ciencia, IBIMA, Universidad de Málaga, Málaga, Spain. [Tolosa,E] Unidad de Parkinson y movimientos anormales, Servicio de Neurología, Hospital Clínic, Barcelona. [Tolosa,E] Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain. [Tolosa,E] Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain. [Vilas,D] Servicio de Neurología, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Aldecoa,I] Centro de Diagnóstico Biomédico, Departamento de Patología, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. [Aldecoa,I] Banco de Tejidos Neurológicos del Biobanco, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Berenguer,J] Servicio de Radiología, Hospital Clínic, Barcelona, Spain. [Damas-Hermoso.F] Servicio de Neurología, Hospital Universitario de Valme, Sevilla, Spain, This work was supported by grants to E.F.-E. from Junta de Andalucía, Consejería de Economía, Conocimiento, Empresas y Universidad, Spain (ref. BIO127, PAIDI), and Sociedad Andaluza de Neurología (ref. SUBAIA2015/006), to F.R.d.F. from European Regional Development Funds-European Union (ERDF-EU) and EULAC-HEALTH H2020 FATZHEIMER Project (EULACH16/T010131), RETICS Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación, and ERDF-EU (RD16/0017/0001), and ISCIII, ERDF-EU (PI19/01577), and as well as to J.S. from Ministerio de Sanidad, Delegación de Gobierno para el Plan Nacional sobre Drogas (PND 2019/040). J.S. (CPII17/00024) holds 'Miguel Servet II' research contracts from the National System of Health, ISCIII, ERDF-EU.
Subjects: 0301 basic medicine, Saliva, Pathology, Physiology, Clinical Biochemistry, Enfermedad de parkinson, Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm [Medical Subject Headings], Biochemistry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Diseases::Nervous System Diseases::Neurodegenerative Diseases::Lewy Body Disease [Medical Subject Headings], 0302 clinical medicine, Alfa-sinucleína, nitrative stress, Parkinson, biology, medicine.diagnostic_test, Chemistry, Estrés oxidativo, nitration, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Nerve Tissue Proteins::Synucleins::alpha-Synuclein [Medical Subject Headings], medicine.anatomical_structure, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunoassay::Immunoenzyme Techniques::Enzyme-Linked Immunosorbent Assay [Medical Subject Headings], Biomarker (medicine), Immunohistochemistry, Anatomy::Tissues::Connective Tissue [Medical Subject Headings], Antibody, Connective tissue, Chemicals and Drugs::Biological Factors::Biological Markers::Biomarkers, Pharmacological [Medical Subject Headings], medicine.medical_specialty, Nitration, RM1-950, Article, Tejido conectivo, 03 medical and health sciences, α-synuclein, Biopsy, medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy [Medical Subject Headings], lewy-type, Molecular Biology, 3-nitrotyrosine, saliva, Lewy-type, Cell Biology, 030104 developmental biology, Anatomy::Fluids and Secretions::Bodily Secretions::Saliva [Medical Subject Headings], Cytoplasm, parkinson, biology.protein, Therapeutics. Pharmacology, Enfermedad por cuerpos de Lewy, Nitrative stress, Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Basal Ganglia Diseases::Parkinsonian Disorders::Parkinson Disease [Medical Subject Headings], 030217 neurology & neurosurgery, Immunostaining
Abstract: Background. Salivary α-synuclein (aSyn) and its nitrated form, or 3-nitrotyrosine-α-synuclein (3-NT-αSyn), hold promise as biomarkers for idiopathic Parkinson’s disease (IPD). Nitrative stress that is characterized by an excess of 3-nitrotyrosine proteins (3-NT-proteins) has been proposed as a pathogenic mechanism in IPD. The objective is to study the pathological role of native αSyn, 3-NT-αSyn, and 3-NT-proteins in the saliva and submandibulary glands of patients with IPD. Methods. The salivary and serum αSyn and 3-NT-proteins concentration is evaluated with ELISA in patients and controls. Correlations of αSyn and 3-NT-proteins content with clinical features of the disease are examined. Immunohistochemical 3-NT-αSyn expression in submandibulary gland sections is analyzed. Results. (a) Salivary concentration and saliva/serum ratios of native αSyn and 3-NT-proteins are similar in patients and controls, (b) salivary αSyn and 3-NT-proteins do not correlate with any clinical feature, and (c) three patterns of 3-NT-αSyn-positive inclusions are observed on histological sections: rounded “Lewy-type” aggregates of 10–25 µm in diameter, coarse deposits with varied morphology, and spheroid inclusions or bodies of 3–5 µm in diameter. “Lewy-type” and coarse inclusions are observed in the interlobular connective tissue of the gland, and small-sized bodies are located within the cytoplasm of duct cells. “Lewy-type” inclusions are only observed in patients, and the remaining patterns of inclusions are observed in both the patients and controls. Conclusions. The patients’ saliva presents a similar concentration of native αSyn and 3-nitrotyrosine-proteins than that of the controls, and no correlations with clinical features are found. These findings preclude the utility of native αSyn in the saliva as a biomarker, and they indicate the absence of nitrative stress in the saliva and serum of patients. As regards nitrated αSyn, “Lewy-type” inclusions expressing 3-NT-αSyn are observed in the patients, not the controls—a novel finding that suggests that a biopsy of the submandibulary gland, if proven safe, could be a useful technique for diagnosing IPD. Finally, to our knowledge, this is also the first description of 3-NT-αSyn-immunoreactive intracytoplasmic bodies in cells that are located outside the nervous system. These intracytoplasmic bodies are present in duct cells of submandibulary gland sections from all subjects regardless of their pathology, and they can represent an aging or involutional change. Further immunostaining studies with different antibodies and larger samples are needed to validate the data.
Published: 2021

28. Proposta sobre l’ordenació de la cirurgia bariàtrica en població adulta als hospitals públics de Catalunya

Author: Estrada-Sabadell, Maria D., de Lacy, Antonio, Balibrea, José M., Vidal, Josep, Moreno, Pau, del Castillo, Daniel, Vives, Margarida, Vilallonga Puy, Ramón, Mauri, Sílvia, Casanovas-Guitart, Cristina, Guarga-Rojas, Alejandro, Pozuelo, Alfonso, Vela-Vallespín, Emili, Biondo, Sebastiano, Prat, Josep, Pons-Vigués, Mariona, [Estrada MD] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQUAS), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Lacy A, Balibrea J, Vidal J] Hospital Clínic, Barcelona, Spain. [Moreno P] Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Castillo D, Vives M] Hospital Sant Joan de Reus, Reus, Spain. [Vilallonga R] Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Mauri S] Hospital Josep Trueta, Girona, Spain. [Casanovas-Guitart C, Guarga A, Pons M, Pozuelo A, Vela E] Servei Català de la Salut (CatSalut), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Biondo S] Societat Catalana de Cirurgia, Barcelona, Spain. [Prat J] Societat Catalana de Cirurgia Plàstica Reparadora i Estètica, Barcelona, Spain, and Departament de Salut
Subjects: instalaciones, servicios y personal de asistencia sanitaria::centros sanitarios::hospitales::hospitales públicos [ATENCIÓN DE SALUD], personas::Grupos de Edad::adulto [DENOMINACIONES DE GRUPOS], Persons::Age Groups::Adult [NAMED GROUPS], Catalonia, terapéutica::manejo de la obesidad::bariatría::cirugía bariátrica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Obesitat - Cirurgia, Therapeutics::Obesity Management::Bariatrics::Bariatric Surgery [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Cataluña, Hospitals públics, Health Care Facilities, Manpower, and Services::Health Facilities::Hospitals::Hospitals, Public [HEALTH CARE]
Abstract: Cirugía bariátrica; Hospitales públicos; Adultos Bariatric surgery; Public hospitals; Adults Cirurgia bariàtrica; Hospitals públics; Adults L'objectiu és definir les indicacions de cirurgia bariàtrica en població adulta i disminuir la variabilitat entre centres hospitalaris; analitzar i definir els diferents nivells quirúrgics segons la complexitat de la cirurgia bariàtrica en població adulta; definir el seguiment a curt/mitjà i llarg termini de la postcirurgia bariàtrica en població adulta i establir els criteris i requeriments mínims dels centres hospitalaris per dur a terme cirurgia bariàtrica en població adulta. L’àmbit d’aplicació del consens és el Sistema sanitari integral d’utilització pública de Catalunya (SISCAT). El objetivo es definir las indicaciones de cirugía bariátrica en población adulta y disminuir la variabilidad entre centros hospitalarios; analizar y definir los diferentes niveles quirúrgicos segundos la complejidad de la cirugía bariátrica en población adulta; definir el seguimiento a corto/medio y largo plazo de la postcirugía bariátrica en población adulta y establecer los criterios y requerimientos mínimos de los centros hospitalarios para llevar a cabo cirugía bariátrica en población adulta. El ámbito de aplicación del consenso es el Sistema sanitario integral de utilización pública de Cataluña (SISCAT). The aim is to define the indications for bariatric surgery in the adult population and to decrease the variability between hospitals; analyze and define the different surgical levels according to the complexity of bariatric surgery in the adult population; define the short / medium and long-term follow-up of bariatric surgery in the adult population and establish the minimum criteria and requirements for hospitals to carry out bariatric surgery in the adult population. The scope of the consensus is the Comprehensive Health System for Public Use in Catalonia (SISCAT).
Published: 2021

29. The role of bronchoscopy in patients with SARS-CoV-2 pneumonia

Author: Iker Fernández-Navamuel, Andrés Giménez Velando, Ricardo García Luján, Albert Sánchez-Font, Alfons Torrego Fernández, Marisol Arenas-De Larriva, Ana Núñez-Ares, Javier Cosano Povedano, Rosa Cordovilla, Roberto Larrosa-Barrero, Andrés Briones-Gómez, Felipe Andreo García, Roberto Martín-DeLeon, Jose Joaquin Cebrian Gallardo, Javier Flandes, Manuel Luis Rodríguez-Perálvarez, Ricardo Aguilar-Colindres, Gorane Iturricastillo, Olga Rajas, Enrique Cases Viedma, Carmen Fernández-Arias, Manuel Nuñez Delgado, Carmen Centeno Clemente, José Franco, Blanca Urrutia Royo, Maria del Mar Valdivia Salas, Albert Rafecas Codern, Virginia Pajares Ruiz, Lorena Comeche Casanova, María Pavón-Masa, Ruth García García, Laura Nuñez García, [Arenas-De Larriva,M] Dept of Bronchoscopy and Interventional Pulmonology, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. [Martín-DeLeon,R] Dept of Pulmonology, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. [Urrutia Royo,B] Pulmonary Dept, Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Fernández-Navamuel,I, Gimenez Velando,A, Nuñez García,L] Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Dept, Hospital Fundacion Jimenez Diaz, ISS-FJD, CIBERES, Madrid, Spain. [Centeno Clemente,C, Andreo García,F] Interventional Pulmonology Unit, Pulmonary Dept, Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, UAB, IGTP, Badalona, Spain. [Rafecas Codern,A, Fernández-Arias,C, Pajares Ruiz,V, Torrego Fernández,A] Respiratory Dept, Hospital Santa Creu i Sant Pau, Barcelona, Spain. [Rajas,O] Interventional Pulmonology Unit, Pulmonology Dept, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Madrid, Spain. [Iturricastillo,G] Pulmonology Dept, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Madrid, Spain. [Garcia Lujan,R] Dept of Interventional Pulmonology, Hospital Universitario 12 Octubre and Hospital Univesitario Quirónsalud Madrid, Madrid, Spain. [Comeche Casanova,L] Dept of Pulmonology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain. [Sánchez-Font,A] Pulmonology Dept, Hospital del Mar, CIBERES, UAB, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. [Aguilar-Colindres,R] Pulmonology Dept, Hospital del Mar, CIBERES, Barcelona, Spain. [Larrosa-Barrero,R] Pulmonary Dept, Hospital Universitario Clínico San Carlos, Madrid, Spain. [García García,R, Cordovilla,R] Interventional Pulmonology Unit, Pulmonary Dept, Salamanca University Hospital, Salamanca, Spain. [Núñez-Ares,A] Interventional Pulmonology Unit, Pulmonary Dept, Albacete, Spain. [Briones-Gómez,A, Cases Viedma,E] Interventional Pulmonology Unit, Pulmonary Dept, Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Franco,J] Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. [Cosano Povedano,J] Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Dept, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. [Rodríguez-Perálvarez,ML] Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), CIBERehd, Córdoba, Spain. [Cebrian Gallardo,JJ] Dept of Pulmonology, Agencia sanitaria Costa del Sol, Marbella, Spain. [Nuñez Delgado,M] Dept of Bronchoscopy and Interventional Pulmonology, Hospital Álvaro Cunqueiro, CHUVI, Vigo, Spain. [Pavón-Masa,M] Dept of Interventional Pulmonology, Hospital Universitario Virgen Macarena, Seville, Spain. [Valdivia Salas,MDM] Dept of Interventional Pulmonology, Hospital Universitario Santa Lucía, Cartagena, Spain. [Flandes,J] Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Dept, Hospital Fundación Jimenez Diaz, ISS-FJD, CIBERES, Madrid, Spain., and The present study was funded by the Spanish Society of Pulmonology and Thoracic Surgery: extraordinary grant PII 2020 for research in COVID-19.
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Moco, medicine.medical_treatment, Check Tags::Male [Medical Subject Headings], Broncoscopía, medicine.disease_cause, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Respiratory System::Bronchoscopy [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Respiratory Therapy::Respiration, Artificial [Medical Subject Headings], Bronchoscopies, law.invention, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 03 medical and health sciences, Hyperaemia, 0302 clinical medicine, Bronchoscopy, law, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Models, Theoretical::Models, Statistical::Logistic Models [Medical Subject Headings], Internal medicine, Neumonía, medicine, 030212 general & internal medicine, Anatomy::Fluids and Secretions::Bodily Secretions::Mucus [Medical Subject Headings], Mechanical ventilation, medicine.diagnostic_test, business.industry, SARS-CoV-2, COVID-19, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality [Medical Subject Headings], Pneumonia, medicine.disease, Intensive care unit, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Mucus, 030228 respiratory system, Superinfection, Cohort, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings], Medicine, Original Article, medicine.symptom, business
Abstract: BackgroundThe role of bronchoscopy in coronavirus disease 2019 (COVID-19) is a matter of debate.Patients and methodsThis observational multicentre study aimed to analyse the prognostic impact of bronchoscopic findings in a consecutive cohort of patients with suspected or confirmed COVID-19. Patients were enrolled at 17 hospitals from February to June 2020. Predictors of in-hospital mortality were assessed by multivariate logistic regression.ResultsA total of 1027 bronchoscopies were performed in 515 patients (age 61.5±11.2 years; 73% men), stratified into a clinical suspicion cohort (n=30) and a COVID-19 confirmed cohort (n=485). In the clinical suspicion cohort, the diagnostic yield was 36.7%. In the COVID-19 confirmed cohort, bronchoscopies were predominantly performed in the intensive care unit (n=961; 96.4%) and major indications were: difficult mechanical ventilation (43.7%), mucus plugs (39%) and persistence of radiological infiltrates (23.4%). 147 bronchoscopies were performed to rule out superinfection, and diagnostic yield was 42.9%. There were abnormalities in 91.6% of bronchoscopies, the most frequent being mucus secretions (82.4%), haematic secretions (17.7%), mucus plugs (17.6%), and diffuse mucosal hyperaemia (11.4%). The independent predictors of in-hospital mortality were: older age (OR 1.06; pConclusionBronchoscopy may be indicated in carefully selected patients with COVID-19 to rule out superinfection and solve complications related to mechanical ventilation. The presence of haematic secretions in the distal bronchial tract may be considered a poor prognostic feature in COVID-19.
Published: 2021

30. Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience

Author: Paloma Gastelurrutia, Cristina Prat-Vidal, Joaquim Vives, Ruth Coll, Antoni Bayes-Genis, Carolina Gálvez-Montón, Institut Català de la Salut, [Gastelurrutia P, Prat-Vidal C] Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Spain. Insuficiencia Cardíaca y Regeneración Cardíaca Research Program, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain. Centro de Investigación Biomédica en Red Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain. [Vives J] Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Barcelona, Spain. Grup d’Enginyeria tissular musculoesquelètica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Coll R] Servei de Teràpia Cel·lular, Banc de Sang i Teixits, Barcelona, Spain. [Bayes-Genis A] Insuficiencia Cardíaca y Regeneración Cardíaca Research Program, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain. Centro de Investigación Biomédica en Red Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain. Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gálvez-Montón C] Insuficiencia Cardíaca y Regeneración Cardíaca Research Program, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain. Centro de Investigación Biomédica en Red Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Therapeutics::Therapies, Investigational [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], 0301 basic medicine, regulatory agency, lcsh:Diseases of the circulatory (Cardiovascular) system, medicine.medical_specialty, terapéutica::tratamientos en investigación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], media_common.quotation_subject, Cellular therapy, Investigació mèdica, Cardiovascular Medicine, 030204 cardiovascular system & hematology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Policy and Practice Reviews, Medicine research, medicine, Quality (business), Medical physics, Product (category theory), media_common, Medicaments - Desenvolupament, investigational medicinal product dossier (IMPD), localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS], translational (regulation), Medicina basada en l'evidència, business.industry, Teràpia cel·lular, Medicina - Investigació - Espanya, Geographic Locations::Europe::Spain [GEOGRAPHICALS], 030104 developmental biology, investigational medicinal product, chemistry, Natural Science Disciplines::Science::Research::Biomedical Research::Translational Medical Research [DISCIPLINES AND OCCUPATIONS], lcsh:RC666-701, New product development, disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica::investigación médica traslacional [DISCIPLINAS Y OCUPACIONES], advanced therapy medicinal product, Regulatory agency, ATMP, Cardiology and Cardiovascular Medicine, business
Abstract: Medicament de teràpia avançada; Medicament en investigació; Translacional (regulació) Medicamento de terapia avanzada; Medicamento en investigación; Traslacional (regulación) Advanced therapy medicinal product; Investigational medicinal product; Translational (regulation) A systematic and ordered product development program, in compliance with current quality and regulatory standards, increases the likelihood of yielding a successful advanced therapy medicinal product (ATMP) for clinical use as safe and effective therapy. As this is a novel field, little accurate information is available regarding the steps to be followed, and the information to be produced to support the development and use of an ATMP. Notably, successful clinical translation can be somewhat cumbersome for academic researchers. In this article, we have provided a summary of the available information, supported by our experience in Spain throughout the development of an ATMP for myocardial infarction, from the pre-clinical stage to phase I clinical trial approval. This work was supported by the Spanish Cell Therapy Network (TerCel) [RD16/0011/0006 and RD16/0011/0028]; and CIBER Cardiovascular [CB16/11/00403] projects, as a part of the National R&D&I Plan, and was co-funded by the ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF); the Government of Catalonia: Agency for Management of University and Research Grants (AGAUR) [2017-SGR-483 and 2017-SGR-719], PERIS Program (Health Department) [SLT002/16/00234 and SLT002/16/00209] and CERCA Program; La Caixa Banking Foundation; grants from the Spanish Ministry of Science, Innovation and Universities (MICINN) [SAF2017-84324-C2-1-R]; Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, and PI19/01788], and cofunded by European Union (ERDF/ESF) - A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Center for Regenerative Medicine of Barcelona (CMR[B]). The funders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
Published: 2021

31. Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

Author: [Ruiz de Porras V, Bystrup S, Cabrero-de Las Heras S] Program of predictive and personalized cancer medicine (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Badalona, Spain. [Musulén E] Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Valles, Spain. [Palomero L] Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, L’Hospitalet del Llobregat, Spain. ONCOBELL Program, Bellvitge Institute for Biomedical Research, L’Hospitalet del Llobregat, Spain. [Henar Alonso M] ONCOBELL Program, Bellvitge Institute for Biomedical Research, L’Hospitalet del Llobregat, Spain. Oncology Data Analytics Program, Institut Català d’Oncologia (ICO), Barcelona, Sapin. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. [Nieto R, Arango D] Grup de Recerca en Investigació Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain and Hospital Universitari Vall d'Hebron
Subjects: Quinases dependents de ciclina, Marcadors tumorals, Digestive System Diseases::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Digestive System Diseases::Digestive System Diseases::Digestive System Diseases::Digestive System Diseases::Colorectal Neoplasms [DISEASES], Recte - Càncer, factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Enfermedades del Sistema Digestivo::Neoplasias del Sistema Digestivo::Neoplasias Gastrointestinales::Neoplasias Intestinales::Enfermedades del Sistema Digestivo::Enfermedades del Sistema Digestivo::Enfermedades del Sistema Digestivo::Enfermedades del Sistema Digestivo::Neoplasias Colorrectales [ENFERMEDADES], Enzimas y Coenzimas::Enzimas::Transferasas::Fosfotransferasas::Fosfotransferasas (Aceptor de Grupo Alcohol)::Proteínas Quinasas::Proteínas Serina-Treonina Quinasas::Proteínas Quinasas Dirigidas por Prolina::Quinasas Ciclina-Dependientes::Quinasas CDC2-CDC28::Quinasa 5 Dependiente de la Ciclina [COMPUESTOS QUÍMICOS Y DROGAS], Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Proline-Directed Protein Kinases::Cyclin-Dependent Kinases::CDC2-CDC28 Kinases::Cyclin-Dependent Kinase 5 [CHEMICALS AND DRUGS]
Published: 2021

32. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Author: Gonzalez Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer Palter, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera Álvarez, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, 1953, Martinez Picado, Javier, Cerezuela, Pablo, Soria, Ainara, Marquez, Ivan, Mandala, Mario, Berrocal, Alfonso, Spanish Melanoma Group (GEM)., Institut Català de la Salut, [Gonzalez-Cao M] Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain. [Puertolas T] Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain. [Riveiro M] Unitat del Fetge, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Muñoz-Couselo E, Ortiz C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Paredes R] IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain. Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Oncology, Cancer Research, Skin Neoplasms, Advisory committee, medicine.medical_treatment, Immunoteràpia, Comorbidity, Medical Oncology, 0302 clinical medicine, Cancer immunotherapy, Risk Factors, Immunology and Allergy, 030212 general & internal medicine, Càncer, Immune Checkpoint Inhibitors, Melanoma, Otros calificadores::/terapia [Otros calificadores], RC254-282, Cancer, Evidence-Based Medicine, Latent tuberculosis, terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunosuppression, Treatment Outcome, 030220 oncology & carcinogenesis, Molecular Medicine, immunotherapy, Viral hepatitis, medicine.medical_specialty, Consensus, Immunology, Immunotheraphy, Communicable Diseases, Risk Assessment, neoplasias [ENFERMEDADES], Immunocompromised Host, 03 medical and health sciences, Internal medicine, Position Article and Guidelines, medicine, Humans, In patient, Pharmacology, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], business.industry, Other subheadings::/therapy [Other subheadings], Immunotherapy, medicine.disease, Neoplasms [DISEASES], Càncer - Immunoteràpia, business
Abstract: Immunoteràpia Inmunoterapia Immunotherapy Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities. This work was supported by the Spanish Melanoma Group (GEM).
Published: 2021

33. Use and safety of remdesivir in kidney transplant recipients with COVID-19

Author: Maria Luisa Martin, Cristina Canal, Carlos Arias-Cabrales, Antonio Franco, Francesc Moreso, Isabel María Saura, Luis Sanchez-Cámara, Sofía Zárraga, Sheila Cabello Pelegrin, Julio Pascual, Emilio Sánchez-Álvarez, Inmaculada Lorenzo, Anna Buxeda, Raquel Santana-Estupiñán, Edoardo Melilli, María José Aladrén, Esperanza Moral Berrio, Judit Cacho, Marta Crespo, Orlando Siverio, Auxiliadora Mazuecos, José Portolés, Verónica López, Elena González-García, Paloma L Martin-Moreno, Iñigo Moina, María José Pérez-Sáez, Cristina Galeano, María del Carmen Ruiz-Fuentes, Institut Català de la Salut, [Buxeda A, Arias-Cabrales C, Pérez-Sáez MJ] Department of Nephrology, Hospital del Mar, Institute Mar for Medical Research (IMIM), Red de Investigación Renal (REDinREN) (RD16/0009/0013), Barcelona, Spain. [Cacho J] Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Cabello Pelegrin S] Department of Nephrology, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Melilli E] Department of Nephrology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain. [Moreso F] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: medicine.medical_specialty, enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::lesión renal aguda [ENFERMEDADES], medicine.medical_treatment, Trasplantament renal, Remdesivir, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Injury, Other subheadings::Other subheadings::/drug therapy [Other subheadings], law.invention, Kidney transplantation, SARS-CoV2l, Randomized controlled trial, COVID-19 (Malaltia) - Tractament, law, Clinical Research, Internal medicine, medicine, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Adverse effect, business.industry, SARS-CoV-2, Acute kidney injury, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Immunosuppression, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], medicine.disease, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Acute Kidney Injury [DISEASES], Discontinuation, Insuficiència renal aguda, Nephrology, SARS-CoV2, Cohort, Avaluació de resultats (Assistència sanitària), Acute kidney, business, Cohort study
Abstract: Introduction:Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time torecovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acutekidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidneytransplant recipients.Methods:We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treatedwith remdesivir. Outcomes and safety were assessed.Results:Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) requiredmechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged$65 years(45% vs. 3.2% in younger patients). Acute kidneyinjury was present in 27.7% of patients, but wasdiagnosed in 50% before treatment. No patients required remdesivir discontinuation because ofadverse events. We did notfind significant hepatoxicity or systemicsymptoms resulting from thedrug. Conclusion:In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renaland hepatic toxicity, but randomized trials are needed to assess its efficacy. The authors are indebted to the many physicians andnurses who take care of these patients and are facing theCOVID-19 pandemic in our country. This research wassupported by Rio Hortega contract CM19/00004 (ISCIII)(AB), and RD16/0009/0013 (ISCIII FEDER RedinRen). MJP-S is supported by a Spanish Society of Transplantscholarship
Published: 2021

34. Predictive model for atrial fibrillation in hypertensive diabetic patients

Author: Miguel Angel Muñoz, Alejandro Bustamante, Elena Palà, José Luis del Val-García, Alonso Pedrote, Josep Lluís Clua-Espuny, Felipe Gonzalez-Loyola, Joan Montaner, Rosa Abellana, Domingo Ribas Segui, Jose-Maria Verdu-Rotellar, Institut Català de la Salut, [Abellana R] Biostatistics, Department of Basic Clinical Practice, University of Barcelona, Barcelona, Spain. [Gonzalez-Loyola F] Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat de Suport a la recerca de Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. [Verdu-Rotellar JM] Unitat de Suport a la recerca de Barcelona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. Gerència Atenció Primària Barcelona Ciutat, Institut Català de la Salut, Barcelona, Spain. [Bustamante A] Stroke Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Palà E, Montaner J] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Clua-Espuny JL] Equip Atenció Primària, Tortosa 1-Est, Institut Català Salut, Servei Atenció Primària, UUDD Terres De l’Ebre, Tortosa, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, Clinical Biochemistry, Heart Valve Diseases, 030204 cardiovascular system & hematology, Biochemistry, 0302 clinical medicine, Heart Rate, Atrial Fibrillation, atrial fibrillation, 030212 general & internal medicine, Myocardial infarction, Medicina personalitzada, Stroke, Avaluació del risc per la salut, Aged, 80 and over, Peripheral Vascular Diseases, education.field_of_study, Diabetis, diabetes, valvular heart disease, Age Factors, Atrial fibrillation, General Medicine, Middle Aged, Hypertension, Cardiology, Female, medicine.medical_specialty, hypertension, Population, enfermedades cardiovasculares::enfermedades cardíacas::arritmias cardíacas::fibrilación atrial [ENFERMEDADES], 03 medical and health sciences, Health risk assessment, Sex Factors, Internal medicine, Clinical Decision Rules, medicine, Diabetes Mellitus, Fibril·lació auricular, Humans, Obesity, education, Antihypertensive Agents, Aged, Proportional Hazards Models, Heart Failure, business.industry, prediction models, medicine.disease, Blood pressure, Heart failure, incidence, business, Cardiovascular Diseases::Heart Diseases::Arrhythmias, Cardiac::Atrial Fibrillation [DISEASES], Kidney disease
Abstract: Diabetes; Hpertension; Prediction models Diabetes; Hipertensión; Modelos de predicción Diabetis; Hipertensió; Models de predicció Background Several scores to identify patients at high risk of suffering atrial fibrillation have been developed. Their applicability in hypertensive diabetic patients, however, remains uncertain. Our aim is to develop and validate a diagnostic predictive model to calculate the risk of developing atrial fibrillation at five years in a hypertensive diabetic population. Methods The derivation cohort consisted of patients with both hypertension and diabetes attended in any of the 52 primary healthcare centres of Barcelona; the validation cohort came from the 11 primary healthcare centres of Terres de l’Ebre (Catalonia South) from January 2013 to December 2017. Multivariable Cox regression identified clinical risk factors associated with the development of atrial fibrillation. The overall performance, discrimination and calibration of the model were carried out. Results The derivation data set comprised 54 575 patients. The atrial fibrillation rate incidence was 15.3 per 1000 person/year. A 5-year predictive model included age, male gender, overweight, heart failure, valvular heart disease, peripheral vascular disease, chronic kidney disease, number of antihypertensive drugs, systolic and diastolic blood pressure, heart rate, thromboembolism, stroke and previous history of myocardial infarction. The discrimination of the model was good (c-index = 0.692; 95% confidence interval, 0.684-0.700), and calibration was adequate. In the validation cohort, the discrimination was lower (c-index = 0.670). Conclusions The model accurately predicts future atrial fibrillation in a population with both diabetes and hypertension. Early detection allows the prevention of possible complications arising from this disease.
Published: 2021

35. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study

Author: Anna Hernández-Rubio, Arantza Sanvisens, Eva Faure, Néstor Espinach, Joan Colom, Robert Muga, Xavier Majó, Inmaculada Rivas, [Sanvisens A] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Rivas I, Faure E, Espinach N] Mental Health and Addiction Service, Badalona Serveis Assistencials-BSA, Badalona, Spain. [Hernandez-Rubio A, Muga R] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. [Majó X, Colom J] Programa de Prevenció, Control i Atenció al VIH, les MTS i les Hepatitis Víriques, Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain, and Departament de Salut
Subjects: Adult, Male, medicine.medical_specialty, Longitudinal study, terapéutica::farmacoterapia::tratamiento de sustitución de opiaceos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], viruses, Hepatitis C virus, Observational Study, HIV Infections, Hepacivirus, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Human immunodeficiency virus infection, Internal medicine, medicine, Opioid Treatment Program, Humans, Longitudinal Studies, Drug use, enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH [ENFERMEDADES], Opioid agonist therapy, business.industry, Coinfection, Gastroenterology, virosis::hepatitis viral humana::hepatitis C [ENFERMEDADES], Virus Diseases::Hepatitis, Viral, Human::Hepatitis C [DISEASES], General Medicine, Hepatitis C, Chronic, Middle Aged, Hepatitis C, Infeccions per VIH - Tractament, Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [DISEASES], Analgesics, Opioid, Opioid, 030220 oncology & carcinogenesis, Direct-acting antiviral agents, Hepatitis C virus infection, 030211 gastroenterology & hepatology, Female, business, Virus de l'hepatitis C - Tractament, Opiacis - Ús terapèutic, medicine.drug, Therapeutics::Drug Therapy::Opiate Substitution Treatment [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Abstract: Direct-acting antiviral agents; Opioid Treatment Program; Opioid agonist therapy; Hepatitis C virus infection; Human immunodeficiency virus infection; Drug use Agentes antivirales de acción directa; Programa de Tratamiento de Opioides; Terapia con agonistas opioides; Infección por el virus de la hepatitis C; Infección por el virus de la inmunodeficiencia humana; Uso de drogas Agents antivirals d'acció directa; Programa de tractament amb opioides; Teràpia amb agonistes opioides; Infecció pel virus de l'hepatitis C; Infecció pel virus de la immunodeficiència humana; Ús de drogues Background: Direct-acting antivirals (DAAs) are recommended for the treatment of hepatitis C virus (HCV) infection in patients treated with methadone or buprenorphine. Aim: To assess HCV treatment rates in an Opioid Treatment Program (OTP). Methods: This longitudinal study included 501 patients (81.4% men, median age: 45 years; interquartile range: 39-50 years) enrolled in an OTP between October 2015 and September 2017. Patients were followed until September 2019. Data on socio-demographics, substance use, HCV infection, human immunodeficiency virus (HIV) infection and laboratory parameters were collected at entry. We analyzed medical records to evaluate HCV treatment. Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors. Results: Prevalence of HCV and HIV infection was 70% and 34%, respectively. Among anti-HCV-positive (n = 336) patients, 47.2%, 41.3%, and 31.9% used alcohol, cannabis, and cocaine, respectively. HCV-RNA tests were positive in 233 (69.3%) patients. Twentyeight patients (8.3%) cleared the infection, and 59/308 (19.1%) had received interferon-based treatment regimens before 2015. Among 249 patients eligible, 111 (44.6%) received DAAs. Treatment rates significantly increased over time from 7.8/100 person-years (p-y) (95%CI: 5.0-12.3) in 2015 to 18.9/100 p-y (95%CI: 11.7-30.3) in 2019. In a multivariate analysis, patients with HIV co-infection were twice as likely to receive DAAs (HR = 1.94, 95%CI: 1.21-3.12) than patients with HCV mono-infection. Current drug use was an independent risk factor for not receiving treatment against infection (HR = 0.48, 95%CI: 0.29-0.80). Conclusion: HCV treatment is evolving in patients with HCV-HIV co-infection. Ongoing drug use while in an OTP might negatively impact the readiness to treat infection. Supported by the Ministry of Science, Innovation and Universities, Carlos III Health Institute (ISCIII), European Fund for Regional Development (FEDER), Network for Cooperative Research in Health (RETICS), Spain (No. RD16/0017/0003, PI17/00174, INT19/00026, CD19/00019); the Ministry of Health, National Plan on Drugs (PNSD), Spain (No. 2018/020); the European Commission (806996- JUSTSO-JUST2017-AG-DRUG); the Gilead Fellowship Program, Gilead Sciences (No. GLD17/187); the Ministry of Education, Spain (No. PRX18/00245); the Agency for Management of University and Research Grants, Government of Catalonia (No. 2017SGR316); and the Municipal Institute of Personal Services-IMSP, Badalona.
Published: 2020

36. Bronchoscopist's perception of the quality of the single-use bronchoscope (Ambu aScope4™) in selected bronchoscopies: a multicenter study in 21 Spanish pulmonology services

Author: Flandes, Javier, Giraldo-Cadavid, Luís Fernando, Alfayate, Javier, Fernández-Navamuel, Iker, Agusti, Carlos, Lucena, Carmen M., Rosell, Antoni, Andreo, Felipe, Centeno, Carmen, Montero, C., Vidal, Iria, García-Alfonso, Lucía, Bango, Antonio, Ariza, Miguel, Gallego, Rocío, Orta, Marta, Bello, Salvador, Mincholé, Elisa, Torrego, Alfons, Pajares, Virginia, González, Héctor, Wangüemert, Aurelio Luís, Pérez-Izquierdo, Julio, Disdier, Carlos, de Vega Sanchez, Blanca, Cordovilla, Rosa, Cascón, Juan, Cruz, Antonio, García-López, J.Javier, Puente, Luis, Benedetti, Paola, García-Gallo, Cristina L., Díaz Nuevo, Gema, Aguado, Silvia, Partida, Concepción, Díaz-Agero, Prudencio, Luque Crespo, Estefania, Pavón, María, Páez, Francisco, Cases, Eenrique, Martínez, Raquel, Briones, Andrés, Fernández, Cleofe, Martín Serrano, Concepción, Uribe-Hernández, Ana María, Robles, Jose, Universitat Autònoma de Barcelona, [Flandes,J, Alfayate,J, Fernández‑Navamuel,I] Pneumology Service, Bronchoscopy and Interventional Pulmonology Unit, University Hospital 'Fundación Jiménez Díaz', ISS-FJD CIBERES, Madrid, Spain.[Giraldo‑Cadavid,LF] Interventional Pulmonology, Fundación Neumológica Colombiana, Profesor Titular Universidad de La Sabana, Bogotá, DC, Colombia. [Agusti,C, Lucena,CM] Department of Epidemiology and Biostatistics, School of Medicine, Universidad de La Sabana, La Caro, Chía, Colombia. [Rosell,A] Pneumology Service, Hospital Clínic Universitari, Barcelona, Spain. [Andreo,F, Centeno,C] Pneumology Service, Hospital Universitari de Bellvitge, Barcelona, Spain. [Montero,C, Vidal,I, García-Alfonso,L] Pneumology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. [Bango,A, Ariza,M] Pulmonology Service, Complexo Hospitalario Universitario, A Coruña, Spain. [Gallego,R, Orta,M] Pneumology Service, Central University Hospital of Asturias, Oviedo Asturias, Spain. [Bello,S, incholé,E] Pneumology Service, Hospital San Pedro de Alcántara, Cáceres, Spain. [Torrego, Pajares,V] Pneumology Service, Miguel Servet University Hospital, Zaragoza, Spain. [González,H] Pneumology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Wangüemert,AL] Pneumology Service, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain. [Pérez‑Izquierdo,J] Pneumology Service, Hospital San Juan de Dios, Santa Cruz de Tenerife, Spain. [Disdier,C, de Vega Sanchez,B] Pneumology Service, Galdakao University Hospital, Bilbao Vizcaya, Spain. [Cordovilla,R, Cascón,J, Cruz,A] Pneumology Service, Hospital Clínico Universitario, Valladolid, Spain. [García‑López,JJ, Puente,L, Benedetti,P] Pneumology Service, University Assistance Complex, Salamanca, Spain. [García‑Gallo,CL, Díaz Nuevo,G, Aguado,G] Pneumology Service, Hospital Universitario Gregorio Marañón, Madrid, Spain. [Partida,C, Díaz‑Agero,P]Pneumology Service, Puerta de Hierro University Hospital, Madrid, Spain. [Luque Crespo,E, Pavón,M]Thoracic Surgery Service, Hospital Universitario La Paz, Madrid, Spain. [Páez,F] Pneumology Service, Virgen de Macarena University Hospital, Seville, Spain. [Cases,E, Martínez,R, Briones,A] Pneumology Service, Carlos Hay Regional University Hospital, Malaga, Spain. [Fernández,C, and Martín Serrano,C] Respiratory Endoscopy Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain. [Uribe‑Hernández,AM] Pneumology Service, General University Hospital, Alicante, Spain. [Robles,J] Fundación Neumológica Colombiana, Bogotá, DC, Colombia. [Giraldo‑Cadavid,LF] Industrial Electronic Engineering, GHS SL, Madrid, Spain.
Subjects: Bronchoscopist, Health Knowledge, Attitudes, Practice, aScope4™, CUSUM, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Bronchoscopy, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Equipment Design [Medical Subject Headings], Broncoscòpia, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Attitude::Attitude to Health::Health Knowledge, Attitudes, Practice [Medical Subject Headings], Medicine, 030212 general & internal medicine, Prospective Studies, aScope4&#8482, Disposable Equipment, media_common, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Thoracic Surgical Procedures::Pulmonary Surgical Procedures::Bronchoscopy [Medical Subject Headings], medicine.diagnostic_test, Equipment Design, Quality, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings], Pulmonology, Bronchoscopes, Pulmonologists, Clinical Competence, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Equipment and Supplies::Disposable Equipment [Medical Subject Headings], Learning Curve, Bronchoalveolar lavage, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Attitude of Health Personnel, media_common.quotation_subject, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Analytical, Diagnostic and Therapeutic Techniques and Equipment::Equipment and Supplies::Diagnostic Equipment::Endoscopes::Bronchoscopes [Medical Subject Headings], Bronchoscopies, CUSUM analysis, 03 medical and health sciences, Internal medicine, Humans, Quality (business), Medical physics, lcsh:RC705-779, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], business.industry, SARS-CoV-2, Research, COVID-19, lcsh:Diseases of the respiratory system, Cross-Sectional Studies, 030228 respiratory system, Multicenter study, Spain, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Health Care Surveys [Medical Subject Headings], Health Care Surveys, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Attitude::Attitude of Health Personnel [Medical Subject Headings], Health Care::Health Services Administration::Quality of Health Care::Clinical Competence [Medical Subject Headings], business, Psychiatry and Psychology::Psychological Phenomena and Processes::Psychology, Applied::Psychology, Educational::Learning::Learning Curve [Medical Subject Headings]
Abstract: Background The disposable bronchoscope is an excellent alternative to face the problem of SARS-CoV-2 and other cross infections, but the bronchoscopist's perception of its quality has not been evaluated. Methods To evaluate the quality of the Ambu-aScope4 disposable bronchoscope, we carried out a cross-sectional study in 21 Spanish pulmonology services. We use a standardized questionnaire completed by the bronchoscopists at the end of each bronchoscopy. The variables were described with absolute and relative frequencies, measures of central tendency and dispersion depending on their nature. The existence of learning curves was evaluated by CUSUM analysis. Results The most frequent indications in 300 included bronchoscopies was bronchial aspiration in 69.3% and the median duration of these was 9.1 min. The route of entry was nasal in 47.2% and oral in 34.1%. The average score for ease of use, image, and aspiration quality was 80/100. All the planned techniques were performed in 94.9% and the bronchoscopist was satisfied in 96.6% of the bronchoscopies. They highlighted the portability and immediacy of the aScope4TM to start the procedure in 99.3%, the possibility of taking and storing images in 99.3%. The CUSUM analysis showed average scores > 70/100 from the first procedure and from the 9th procedure more than 80% of the scores exceeded the 80/100 score. Conclusions The aScope4™ scored well for ease of use, imaging, and aspiration. We found a learning curve with excellent scores from the 9th procedure. Bronchoscopists highlighted its portability, immediacy of use and the possibility of taking and storing images.
Published: 2020

37. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Author: Edoardo Bertero, Linda W. van Laake, Petar M. Seferovic, Ewa A. Jankowska, Javid Moslehi, Frank Ruschitzka, Richard N. Kitsis, Johann Bauersachs, Jean-Sébastien Hulot, Ovidiu Chioncel, Patrycja Nowak-Sliwinska, Joseph Pierre Aboumsallem, Dirk Jäger, Rudolf A. de Boer, Peter van der Meer, Douglas B. Sawyer, Dimitrios Farmakis, Lorenz H. Lehmann, Johannes Backs, Christoph Maack, Carlo G. Tocchetti, Suma H Konety, Massimo F Piepoli, Thomas Thum, Radek Pudil, Oliver J. Müller, Daniel J. Lenihan, James Larkin, Alexander R. Lyon, Pierre Dodion, Thomas M. Suter, Pietro Ameri, Thomas Eschenhagen, Antoni Bayes-Genis, Jelena Čelutkienė, Stephan von Haehling, Peter P. Rainer, Andrew J.S. Coats, Piotr Ponikowski, Stefan D. Anker, Stephane Heymans, Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), University Medical Center Groningen [Groningen] (UMCG), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris] (DMU CARTE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), University of Naples Federico II, Universita degli studi di Genova, IRCCS Ospedale Policlinico San Martino [Genoa, Italy], Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Hannover Medical School [Hannover] (MHH), University Hospital of Würzburg, San Raffaele Pisana Scientific Institute for Resaearch, Hospitalisation, and Health Care, San Raffaele Institute Pisana, Vilnius University [Vilnius], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Innate Pharma, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), University of Cyprus (UCY), National and Kapodistrian University of Athens (NKUA), Hospital Universitari Germans Trias I Pujol [Badalona], Universitat Autònoma de Barcelona (UAB), Instituto de Salud Carlos III [Madrid] (ISC), Heidelberg University Hospital [Heidelberg], Wroclaw Medical University [Wrocław, Pologne], Albert Einstein College of Medicine [New York], University of Minnesota Medical School, University of Minnesota System, Royal Marsden NHS Foundation Trust, Universität Heidelberg [Heidelberg], Washington University in Saint Louis (WUSTL), Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Kiel University, University of Geneva [Switzerland], University of Parma = Università degli studi di Parma [Parme, Italie], University Hospital Hradec Kralove, Medical University of Graz, University hospital of Zurich [Zurich], Maine Medical Center Research Institute (MMCRI), University of Belgrade [Belgrade], University of Bern, Utrecht University [Utrecht], University of Göttingen - Georg-August-Universität Göttingen, Maastricht University [Maastricht], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Imperial College London, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: Carim - H02 Cardiomyopathy
Subjects: Cardiac & Cardiovascular Systems, SYMPATHETIC-NERVOUS-SYSTEM, [SDV]Life Sciences [q-bio], angiogenesis, cancer, cardio-oncology, cardiotoxicity, clonal haematopoiesis, extracellular matrix, heart failure, inflammation, metabolism, Disease, Comorbidity, 030204 cardiovascular system & hematology, Bioinformatics, DISEASE, 0302 clinical medicine, Risk Factors, Neoplasms, CACHEXIA, INCREASED RISK, Cancer, ddc:615, TUMOR-GROWTH, CLONAL HEMATOPOIESIS, Extracellular matrix, 3. Good health, Cardio‐oncology, Cardio-oncology, oncology, Position Paper, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, CARDIAC DYSFUNCTION, DOXORUBICIN, Translational research, Context (language use), Heart failure, Clonal haematopoiesis, RADIATION-EXPOSURE, ANTHRACYCLINE CARDIOTOXICITY, 03 medical and health sciences, Genetic predisposition, medicine, Humans, Clinical significance, Inflammation, Science & Technology, business.industry, Cardio&#8208, medicine.disease, Cardiotoxicity, Metabolism, Cardiovascular System & Cardiology, Personalized medicine, Angiogenesis, business
Abstract: The co‐occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre‐clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time., We describe the co‐occurrence of cancer and heart failure (HF), their potential shared risk factors, and their pathophysiological mechanisms. We advocate intense interaction between cardiologists and oncologists to achieve unifying hypotheses and collaborative pre‐clinical and clinical studies.
Published: 2020

38. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm

Author: Rafael Morales, Baldo Oliva, Raquel Valls, Juan de la Haba-Rodriguez, Jose Barbera, José Manuel Mas, Joaquim Aguirre-Plans, Alex Olvera, Laura Artigas, Mireia Coma, Narcis Fernandez-Fuentes, Pedro Matos-Filipe, Judith Farrés, [Artigas,L, Coma,M, Matos-Filipe,P, Farrés,J, Valls,R, Mas,JM] Anaxomics Biotech, Barcelona, Spain. [Matos-Filipe,P, Aguirre-Plans,J, Oliva,B] Structural Bioinformatics Group, Research Programme on Biomedical Informatics, Department of Experimental and Health Science, Universitat Pompeu Fabra, Barcelona, Catalonia, Spain. [Fernandez-Fuentes,N] Department of Biosciences, U Science Tech, Universitat de Vic-Universitat Central de Catalunya, Vic, Catalonia, Spain. [de la Haba-Rodriguez,J] Maimonides Biomedical Research Institute, Reina Sofia Hospital, University of Cordoba, Cordoba, Spain. [Olvera,A] Institut de Recerca de la Sida-IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona), Spain. [Barbera,J, and Morales,R] Servicio de Medicina interna-Unidad de Infecciosas, La Mancha-Centro Hospital, Alcázar de San Juan, Spain.
Subjects: 0301 basic medicine, RNA viruses, Viral Diseases, Pulmonology, Coronaviruses, Physiology, Databases, Pharmaceutical, Disease, Bioinformatics, Biochemistry, Information Science::Information Science::Medical Informatics::Medical Informatics Applications::Information Systems::Databases as Topic::Databases, Factual::Databases, Pharmaceutical [Medical Subject Headings], Melatonina, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Medical Conditions, Immune Physiology, Medicine, Drug Interactions, Computer Networks, Pathology and laboratory medicine, Melatonin, Furin, Innate Immune System, Multidisciplinary, Respiratory distress, Pharmaceutics, Combined modality therapy, Pirfenidone, Medical microbiology, 3. Good health, Drug repositioning, Infectious Diseases, Viruses, Cytokines, SARS CoV 2, Pathogens, Coronavirus Infections, Cytokine Release Syndrome, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Drug Discovery::Drug Repositioning [Medical Subject Headings], medicine.drug, Research Article, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Combined Modality Therapy [Medical Subject Headings], Computer and Information Sciences, SARS coronavirus, Pyridones, Infecciones por coronavirus, Science, Immunology, Pneumonia, Viral, Microbiology, Antiviral Agents, Sepsis, 03 medical and health sciences, Respiratory Disorders, Pharmacotherapy, Drug Therapy, Humans, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridines::Pyridones [Medical Subject Headings], Pandemics, Medicine and health sciences, Pharmacology, Terapia combinada, business.industry, Septic shock, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Melatonin [Medical Subject Headings], Organisms, Viral pathogens, Drug Repositioning, Biology and Life Sciences, COVID-19, Covid 19, Molecular Development, medicine.disease, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Hormones, Microbial pathogens, COVID-19 Drug Treatment, 030104 developmental biology, Immune System, Respiratory Infections, Antivirales, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Hydrolases::Peptide Hydrolases::Proprotein Convertases::Furin [Medical Subject Headings], business, Cytokine storm, 030217 neurology & neurosurgery, Developmental Biology
Abstract: From January 2020, COVID-19 is spreading around the world producing serious respiratory symptoms in infected patients that in some cases can be complicated by the severe acute respiratory syndrome, sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. Cost and time efficient approaches to reduce the burthen of the disease are needed. To find potential COVID-19 treatments among the whole arsenal of existing drugs, we combined system biology and artificial intelligence-based approaches. The drug combination of pirfenidone and melatonin has been identified as a candidate treatment that may contribute to reduce the virus infection. Starting from different drug targets the effect of the drugs converges on human proteins with a known role in SARS-CoV-2 infection cycle. Simultaneously, GUILDify v2.0 web server has been used as an alternative method to corroborate the effect of pirfenidone and melatonin against the infection of SARS-CoV-2. We have also predicted a potential therapeutic effect of the drug combination over the respiratory associated pathology, thus tackling at the same time two important issues in COVID-19. These evidences, together with the fact that from a medical point of view both drugs are considered safe and can be combined with the current standard of care treatments for COVID-19 makes this combination very attractive for treating patients at stage II, non-severe symptomatic patients with the presence of virus and those patients who are at risk of developing severe pulmonary complications. LA, MC, PMF, JF, RV and JMM have commercial affiliation to Anaxomics Biotech SL. The funders provided support in the form of salaries for authors JAP, NFF and PMF, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. JAP, NFF and BO acknowledge support from the Spanish Ministry of Economy (MINECO) [BIO2017-85329-R] [RYC-2015-17519]; Unidad de Excelencia María de Maeztu”, funded by the Spanish Ministry of Economy [ref: MDM-2014-0370].PMF has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 765912.
Published: 2020
Full Text: View/download PDF

39. Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study

Author: Piar Lianes, J. Coves, Angel Artal, Dolores Isla, José Luis González-Larriba, Enriqueta Felip, Manuel Domine, Enric Carcereny, Pilar Garrido, Nuria Viñolas, Jordi Remon, Rosario García-Campelo, Javier De-Castro, Margarita Majem, Institut Català de la Salut, [Viñolas NN] Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Carrer Villarroel, 170, 08036 Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, Agusti Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Garcia-Campelo R] Medical Oncology Department, Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain. [Majem M] Medical Oncology Department, Instituto H. Santa Creu i Sant Pau, Barcelona, Spain. [Carcereny E] Medical Oncology Department, Hospital Universitari Germans Trias I Pujol, Badalona, Barcelona, Spain. [Isla D] Medical Oncology Department, Hospital Lozano Blesa, Zaragoza, Spain. [Gonzalez-Larriba JL] Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: Male, Longitudinal study, Lung Neoplasms, Exploratory research, 03 medical and health sciences, Social support, Sex Factors, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Sex characteristics, medicine, Humans, Características de la Población::factores socioeconómicos [ATENCIÓN DE SALUD], Longitudinal Studies, Prospective Studies, 030212 general & internal medicine, Lung cancer, General Psychology, Aged, Population Characteristics::Socioeconomic Factors [HEALTH CARE], Carcinoma, Non-small-cell lung, Hazard ratio, Social Support, Respiratory Tract Diseases::Lung Diseases::Lung Neoplasms::Carcinoma, Bronchogenic::Respiratory Tract Diseases::Carcinoma, Non-Small-Cell Lung [DISEASES], Cancer, General Medicine, Middle Aged, medicine.disease, enfermedades respiratorias::enfermedades pulmonares::neoplasias pulmonares::carcinoma broncogénico::enfermedades respiratorias::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Sex Factors [HEALTH CARE], Caregivers, Socioeconomic Factors, 030220 oncology & carcinogenesis, Pulmons - Càncer - Factors sexuals, calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::factores epidemiológicos::factores sexuales [ATENCIÓN DE SALUD], Female, Psychology, Psychosocial, Research Article, Demography
Abstract: Background Little is known about the impact of sex on lung cancer patients from the psychological, economic and social perspectives. This study was designed to explore the psychosocial and economic impact according to sex of metastatic non-small cell lung cancer (mNSCLC) in patients and caregivers. Methods Exploratory study of two cohorts of patients starting first-line treatment for mNSCLC. The following questionnaires were administered at baseline, 4 months later and following the first and second disease progression: APGAR, relationship impact scale, DUKE-UNC scale, economic impact in patients and caregiver, and Zarit scale. It was planned to include 1250 patients to get an 80% possibility of detecting as significant (p Results 333 patients were included. Most families reported to continue being functional despite the lung cancer diagnosis. Regardless of sex, they did not perceive changes in their partner relationship. Most patients felt their social support was normal. Roughly 25% of people reported a worsening in their economic situation, without remarkable differences by sex. Statistically significant differences were found between both groups regarding the caregiver’s relationship to the patient (more parents were the caregiver in females than in males, p p Conclusions This study provides a preliminary insight into sex-related characteristics in the management of advanced NSCLC and its impact on the emotional, social and economic burden of patients and their caregivers, and recall the high priority of researching in cancer from a sex perspective. Nevertheless, due to the low recruitment rate and the relevant loss of patients during the follow-up, it was difficult to find differences by sex. Trial registration ClinicalTrials.gov identifier: NCT02336061. Ethics committee Comité Ético de Investigación Clínica del Hospital Clínic de Barcelona, Spain. Reference number: HCB/2014/0705.
Published: 2020

40. Oral Antibiotic Prophylaxis Lowers Surgical Site Infection in Elective Colorectal Surgery: Results of a Pragmatic Cohort Study in Catalonia

Author: Josep M. Badia, Miriam Flores-Yelamos, Ana Vázquez, Nares Arroyo-García, Mireia Puig-Asensio, David Parés, Miguel Pera, Joaquín López-Contreras, Enric Limón, Miquel Pujol, Members of the VINCat Colorectal Surveillance Team, [Badia JM, Flores-Yelamos M, Arroyo-García N] Department of Surgery, Hospital General Granollers, Granollers, Spain. School of Medicine, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain. [Vázquez A] Servei d’Estadística Aplicada, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain. [Puig-Asensio M] Department of Infectious Diseases, Hospital Universitari de Bellvitge, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), L’Hospitalet del Llobregat, Spain. [Parés D] Department of Surgery, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Pera M] Department of Surgery, Hospital del Mar, Barcelona, Spain. [López-Contreras J] Infectious Disease Unit, Hospital de la Santa Creu i Sant Pau–Institut d’Investigació Biomèdica Sant Pau, Barcelona, Spain. [Limón E] VINCat Program, Barcelona, Spain. Universitat de Barcelona, Barcelona, Spain. [Pujol M] Department of Infectious Diseases, Hospital Universitari de Bellvitge, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005), L’Hospitalet del Llobregat, Spain. VINCat Program, Barcelona, Spain, and Hospital General de Granollers
Subjects: Infeccions quirúrgiques, Multivariate analysis, Surgical wound infection, Còlon - Cirurgia, Logistic regression, Profilaxi antibiòtica oral, Therapeutics::Drug Therapy::Therapeutics::Drug Therapy::Premedication::Antibiotic Prophylaxis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Cirugía colorrectal, Antibiotics, afecciones patológicas, signos y síntomas::procesos patológicos::complicaciones posoperatorias::infección de la herida quirúrgica [ENFERMEDADES], Antibiotic prophylaxis, Univariate analysis, Infecció del lloc quirúrgic, terapéutica::farmacoterapia::terapéutica::farmacoterapia::premedicación::profilaxis antibiótica [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Preparación mecánica del intestino, Mesures preventives, General Medicine, surgical wound infection, Colorectal surgery, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Postoperative Complications::Surgical Wound Infection [DISEASES], profesiones sanitarias::medicina::especialidades quirúrgicas::cirugía colorrectal [DISCIPLINAS Y OCUPACIONES], Medicine, Surgical site infection, Cohort study, medicine.medical_specialty, Cirurgia colorectal, mechanical bowel preparation, Antibiòtics, preventative measures, Article, Profilaxis antibiótica oral, Health Occupations::Medicine::Specialties, Surgical::Colorectal Surgery [DISCIPLINES AND OCCUPATIONS], Internal medicine, Infección del sitio quirúrgico, medicine, Infección de herida quirúrgica, business.industry, oral antibiotic prophylaxis, colorectal surgery, surgical site infection, Medidas preventivas, Infecció, Bowel preparation, Preparació mecànica de l'intestí, Infecció de la ferida quirúrgica, business
Abstract: Colorectal surgery; Mechanical bowel preparation; Oral antibiotic prophylaxis Cirugía colorrectal; Preparación mecánica del intestino; Profilaxis antibiótica oral Cirurgia colorrectal; Preparació mecànica de l'intestí; Profilaxi antibiòtica oral Background: The role of oral antibiotic prophylaxis (OAP) and mechanical bowel preparation (MBP) in the prevention of surgical site infection (SSI) after colorectal surgery is still controversial. The aim of this study was to analyze the effect of a bundle including both measures in a National Infection Surveillance Network in Catalonia. Methods: Pragmatic cohort study to assess the effect of OAP and MBP in reducing SSI rate in 65 hospitals, comparing baseline phase (BP: 2007-2015) with implementation phase (IP: 2016-2019). To compare the results, a logistic regression model was established. Results: Out of 34,421 colorectal operations, 5180 had SSIs (15.05%). Overall SSI rate decreased from 18.81% to 11.10% in BP and IP, respectively (OR 0.539, CI95 0.507-0.573, p < 0.0001). Information about bundle implementation was complete in 61.7% of cases. In a univariate analysis, OAP and MBP were independent factors in decreasing overall SSI, with OR 0.555, CI95 0.483-0.638, and OR 0.686, CI95 0.589-0.798, respectively; and similarly, organ/space SSI (O/S-SSI) (OR 0.592, CI95 0.494-0.710, and OR 0.771, CI95 0.630-0.944, respectively). However, only OAP retained its protective effect at both levels at multivariate analyses. Conclusions: oral antibiotic prophylaxis decreased the rates of SSI and O/S-SSI in a large series of elective colorectal surgery.
Published: 2021

41. Molecular Characterization of Imported and Autochthonous Dengue in Northeastern Spain

Author: Ana Meca Martínez, Anna Vilamala, Mireia Navarro, Aida Peiró-Mestres, Ana Vázquez, Mireia Jané, Miguel J. Martínez, Nuria Torner, Ana Calderón, Josefa Perez, María José Portillo Navarro, Alexander Navarro, María Ángeles Pulido, Rosa Rubio, María Paz Sánchez-Seco, Izaskun Alejo-Cancho, Elena Sulleiro, Jose Muñoz, Josep Barrachina, Daniel Camprubí-Ferrer, Verónica Gonzalo, Rosa Albarracin, Jessica Navero-Castillejos, Carmina Martí, Aroa Silgado, Jaume Llaberia, Rosa Benitez, Montserrat Roldán, Virginia Plasencia, Miguel Micó, Teresa Falgueras, Instituto de Salud Carlos III, Agency for Administration of University and Research, Government of Catalonia (España), Plan Nacional de I+D+i (España), Societat Catalana de Malalties Infeccioses i Microbiologia Clínica, [Navero-Castillejos J] Department of Clinical Microbiology, Hospital Clinic de Barcelona, Barcelona, Spain. Barcelona Institute for Global Health (ISGlobal), Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. [Benitez R] North Metropolitan International Health Unit PROSICS, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Torner N] CIBER Epidemiology and Public Health CIBERESP, University of Barcelona, Barcelona, Spain. [Muñoz J, Camprubí-Ferrer D] Barcelona Institute for Global Health (ISGlobal), Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. [Peiró-Mestres A] Department of Clinical Microbiology, Hospital Clinic de Barcelona, Barcelona, Spain. [Martí C] Hospital General de Granollers, Granollers, Spain, and Hospital General de Granollers
Subjects: Male, Serotype, Microbiologia, Communicable diseases, autochthonous transmission, Dengue virus, medicine.disease_cause, molecular epidemiology, Dengue fever, Dengue, Aedes, Communicable Diseases, Imported, Genotype, Phylogeny, Malalties transmissibles - Transmissió, Surveillance, biology, Middle Aged, QR1-502, Europe, ambiente y salud pública::salud pública::transmisión de una enfermedad infecciosa [ATENCIÓN DE SALUD], Environment and Public Health::Public Health::Disease Transmission, Infectious [HEALTH CARE], Infectious Diseases, Geography, Molecular Diagnostic Techniques, Molecular epidemiology, surveillance, Female, Public Health, Adult, Aedes albopictus, Epidemiologia molecular, Investigative Techniques::Epidemiologic Methods::Molecular Epidemiology [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Autochthonous transmission, Microbiology, Arbovirus, Article, Young Adult, Virology, medicine, Animals, Humans, Aged, Dengue Virus, Malalties infeccioses, medicine.disease, biology.organism_classification, Virus Diseases::Arbovirus Infections::Dengue [DISEASES], dengue, técnicas de investigación::métodos epidemiológicos::epidemiología molecular [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Spain, virosis::infecciones por arbovirus::dengue [ENFERMEDADES]
Abstract: Dengue is the most significant arbovirus worldwide and a public health threat to non-endemic areas in which Aedes vectors are present. Autochthonous dengue transmission has been reported in several European countries in the last decade. Infected travelers from endemic regions arriving to areas colonized by Aedes albopictus in Europe need to be monitored in surveillance and control programs. We aimed to perform molecular characterization of RT-PCR-positive dengue cases detected in Catalonia, northeastern Spain, from 2013 to 2018. The basic demographic information and the geographical regions of importation were also analyzed. One-hundred four dengue cases were studied (103 imported infections and the first autochthonous case in our region). The dengue virus strains detected were serotyped and genotyped using molecular methods, and phylogenetic analyses were conducted. All four dengue serotypes were detected in travelers, including up to 10 different genotypes, reflecting the global circulation of dengue in endemic areas. The primary travel-related case of the 2018 autochthonous transmission was not identified, but the molecular analysis revealed dengue serotype 1, genotype I of Asian origin. Our results highlight the diversity of imported dengue virus strains and the role of molecular epidemiology in supporting arbovirus surveillance programs. This research was partially supported by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR)-Departament d’Empresa i Coneixement. Generalitat de Catalunya (grant 2017 SGR 794 to M.J.M.), by Instituto de Salud Carlos III-Red de Enfermedades Tropicales, Subprograma Redes Temáticas de Investigación Cooperativa en Salud Plan Estatal de I + D + I 2013–2016-Federación Española de Enfermedades Raras [Una Manera de Hacer Europa] (project RD16CIII/0003/0003 to M.P.S.S.) and by Societat Catalana de Malalties Infeccioses i Microbiologia Clínica (grant Agustí Pumarola 2020 to J.N.-C.). Sí
Published: 2021

42. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)

Author: Emilie Le Rhun, Alexander Radbruch, Brigitta G. Baumert, Roberta Rudà, Matthias Preusser, Riccardo Soffietti, Michael Weller, Salvador Villà Freixa, Michael Brada, Sara Kinhult, Joerg C. Tonn, Ufuk Abacioglu, Johan M. Kros, Stephanie E. Combs, Damien C. Weber, Christine Marosi, Carmine M. Carapella, Philippe Metellus, City of Health and Science University Hospital [Turin, Italy], Neolife Medical Center [Istanbul], MediClin Robert-Janker-Klinik [Bonn], Department of Innovative Radiation Oncology and Radiation Sciences [Munich], Skane University Hospital [Lund], Erasmus MC Cancer Institute, Rotterdam, Medizinische Universität Wien = Medical University of Vienna, Hôpital Privé Clairval [Marseille], German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Hospital Universitari Germans Trias I Pujol [Badalona], Department of Molecular and Clinical Cancer Medicine & Radiation Oncology [Liverpool], Regina Elena National Cancer Institute [Rome], University of Vienna [Vienna], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Ludwig-Maximilians-Universität München (LMU), Paul Scherrer Institute (PSI), University hospital of Zurich [Zurich], SALZET, Michel, University of Zurich, Soffietti, Riccardo, University of Munich (LMU Munich), and Pathology
Subjects: Oncology, Cancer Research, medicine.medical_specialty, [SDV]Life Sciences [q-bio], medicine.medical_treatment, 610 Medicine & health, whole-brain radiation therapy, Review, Neuropathology, chemotherapy, Radiosurgery, Targeted therapy, surgery, 03 medical and health sciences, 0302 clinical medicine, brain metastases, Neoplasms, Internal medicine, medicine, Humans, 1306 Cancer Research, neuropathology, Chemotherapy, neuroimaging, Neurologic Oncology, Brain Neoplasms, business.industry, Melanoma, Cancer, targeted therapy, medicine.disease, 10040 Clinic for Neurology, 3. Good health, Surgery, supportive care, [SDV] Life Sciences [q-bio], Radiation therapy, 2728 Neurology (clinical), 030220 oncology & carcinogenesis, Practice Guidelines as Topic, 2730 Oncology, Neurology (clinical), stereotactic radiosurgery/ stereotactic fractionated radiotherapy, business, 030217 neurology & neurosurgery
Abstract: International audience; The management of patients with brain metastases has become a major issue due to the increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014, the European Association of Neuro-Oncology (EANO) created a multidisciplinary Task Force to draw evidence-based guidelines for patients with brain metastases from solid tumors. Here, we present these guidelines, which provide a consensus review of evidence and recommendations for diagnosis by neuroimaging and neuropathology, staging, prognostic factors, and different treatment options. Specifically, we addressed options such as surgery, stereotactic radiosurgery/stereotactic fractionated radiotherapy, whole-brain radiotherapy, chemotherapy and targeted therapy (with particular attention to brain metastases from non-small cell lung cancer, melanoma and breast and renal cancer), and supportive care.
Published: 2017

43. Pertussis prevention : Reasons for resurgence, and differences in the current acellular pertussis vaccines

Author: Susanna Esposito, Paola Stefanelli, Norman K. Fry, Giorgio Fedele, Qiushui He, Pauline Paterson, Tina Tan, Markus Knuf, Carlos Rodrigo, Catherine Weil Olivier, Katie L. Flanagan, Ivan Hung, Iria Lutsar, Kathryn Edwards, Miguel O'Ryan, Nicola Principi, World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Vaccine Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EVASG), [Esposito S] Department of Surgical and Biomedical Sciences, Paediatric Clinic, Università degli Studi di Perugia, Perugia, Italy. [Stefanelli P, Fedele G] Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy. [Fry NK] Immunisation and Countermeasures Division, Public Health England–National Infection Service, London, United Kingdom. [He Q] Institute of Biomedicine, University of Turku, Turku, Finland. Department of Medical Microbiology, Capital Medical University, Beijing, China. [Paterson P] Department of Infectious Disease Epidemiology, The Vaccine Confidence Project TM, London School of Hygiene & Tropical Medicine, London, United Kingdom. [Rodrigo C] Servei de Pediatria, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, lcsh:Immunologic diseases. Allergy, Bordetella pertussis, Whooping Cough, Immunology, Review, Pertussis toxin, pertussis prevention, 03 medical and health sciences, 0302 clinical medicine, Immune system, Vaccines, Acellular, Pertussis prevention, Pertussis, Bacteria::bacterias gramnegativas::bacterias aerobias gramnegativas::bacilos y cocos aerobios gramnegativos::Alcaligenaceae::Bordetella::Bordetella pertussis [ORGANISMOS], medicine, instalaciones, servicios y personal de asistencia sanitaria::servicios de salud::servicios preventivos de salud::programas de inmunización [ATENCIÓN DE SALUD], Immunology and Allergy, Vacunes - Desenvolupament, Humans, Adverse effect, acellular pertussis vaccine, Whooping cough, Tos ferina - Prevenció, Pertussis Vaccine, Acellular pertussis vaccine, biology, Complex Mixtures::Biological Products::Vaccines::Bacterial Vaccines::Pertussis Vaccine [CHEMICALS AND DRUGS], business.industry, pertussis, Bordetel·la pertússica, whole-cell pertussis vaccine, medicine.disease, biology.organism_classification, Whole-cell pertussis vaccine, mezclas complejas::productos biológicos::vacunas::vacunas bacterianas::vacuna de la tos ferina [COMPUESTOS QUÍMICOS Y DROGAS], 030104 developmental biology, Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Alcaligenaceae::Bordetella::Bordetella pertussis [ORGANISMS], Infectious disease (medical specialty), Health Care Facilities, Manpower, and Services::Health Services::Preventive Health Services::Immunization Programs [HEALTH CARE], Pertussis vaccine, Pertactin, business, lcsh:RC581-607, 030215 immunology, medicine.drug
Abstract: Conflict of Interest Statement: SE has received consultancy fees and independent research grants from GlaxoSmithKline group of companies, Sanofi-Pasteur, Merck, Vifor, and DMG. MK was member of advisory boards for GSK, Pfizer, Baxter, Novartis, Astra Zeneca, MedImmune, SPMSD, Sanofi, MSD, Jansen, and performed for these companies presentations during industry symposia. These activities were done as a service task for his employer. Personally, he did not receive any fees from companies. There was also no target agreement with his employer in this respect. MO has received an investigator initiative research grant from Merck to evaluate population perception on hexavalent vs. heptavalent vaccines in Chile. KF is on the vaccine advisory boards for Sanofi Pasteur and Seqiris and have received honoraria from AstraZeneca and Pfizer for giving talks. PP has received research funding from the National Institute for Health Research and from GlaxoSmithKline, and has received honorariums from Sanofi Pasteur and Pfizer. CR has received consultancy fees and independent research grants from GlaxoSmithKline group of companies, Sanofi-Pasteur MSD, Wyeth, Pfizer, Astra-Zeneca, and Astellas. Pertussis is an acute respiratory disease caused by Bordetella pertussis. Due to its frequency and severity, prevention of pertussis has been considered an important public health issue for many years. The development of the whole-cell pertussis vaccine (wPV) and its introduction into the pediatric immunization schedule was associated with a marked reduction in pertussis cases in the vaccinated cohort. However, due to the frequency of local and systemic adverse events after immunization with wPV, work on a less reactive vaccine was undertaken based on isolated B. pertussis components that induced protective immune responses with fewer local and systemic reactions. These component vaccines were termed acellular vaccines and contained one or more pertussis antigens, including pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN), and fimbrial proteins 2 (FIM2) and 3 (FIM3). Preparations containing up to five components were developed, and several efficacy trials clearly demonstrated that the aPVs were able to confer comparable short-term protection than the most effective wPVs with fewer local and systemic reactions. There has been a resurgence of pertussis observed in recent years. This paper reports the results of a Consensus Conference organized by the World Association for Infectious Disease and Immunological Disorders (WAidid) on June 22, 2018, in Perugia, Italy, with the goal of evaluating the most important reasons for the pertussis resurgence and the role of different aPVs in this resurgence.
Published: 2019

44. Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

Author: Ruiz de Porras, V., Bystrup, Sara, Cabrero de las Heras, Sara, Musulén, Eva, Palomero, L., Alonso, M. H., Nieto Raya, Rocio, Arango, Diego, Moreno, V., Queralt, C., Manzano Mozo, José Luís, Layos, Laura, Bugés, Cristina, Martínez Balibrea, Eva, Universitat Autònoma de Barcelona, [Ruiz de Porras V, Bystrup S, Cabrero-de Las Heras S] Program of predictive and personalized cancer medicine (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain. Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, Badalona, Spain. [Musulén E] Department of Pathology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Valles, Spain. [Palomero L] Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology, L’Hospitalet del Llobregat, Spain. ONCOBELL Program, Bellvitge Institute for Biomedical Research, L’Hospitalet del Llobregat, Spain. [Henar Alonso M] ONCOBELL Program, Bellvitge Institute for Biomedical Research, L’Hospitalet del Llobregat, Spain. Oncology Data Analytics Program, Institut Català d’Oncologia (ICO), Barcelona, Sapin. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain. Department of Clinical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. [Nieto R, Arango D] Grup de Recerca en Investigació Biomèdica en Tumors de l'Aparell Digestiu, CIBBIM-Nanomedicine, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
Subjects: 0301 basic medicine, Cancer Research, Colorectal cancer, Digestive System Diseases::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Digestive System Diseases::Digestive System Diseases::Digestive System Diseases::Digestive System Diseases::Colorectal Neoplasms [DISEASES], factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], colorectal cancer, lcsh:RC254-282, Article, Pathogenesis, 03 medical and health sciences, 0302 clinical medicine, Cyclin-dependent kinase, Càncer colorectal, Medicine, Gene silencing, Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], enfermedades del sistema digestivo::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::enfermedades del sistema digestivo::enfermedades del sistema digestivo::enfermedades del sistema digestivo::enfermedades del sistema digestivo::neoplasias colorrectales [ENFERMEDADES], Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Serine-Threonine Kinases::Proline-Directed Protein Kinases::Cyclin-Dependent Kinases::CDC2-CDC28 Kinases::Cyclin-Dependent Kinase 5 [CHEMICALS AND DRUGS], cyclin-dependent kinase 5 (cdk5), biology, business.industry, Kinase, enzimas y coenzimas::enzimas::transferasas::fosfotransferasas::fosfotransferasas (grupo alcohol aceptor)::proteína cinasas::proteína-serina-treonina cinasas::proteínas cinasas dirigidas por prolina::cinasas dependientes de ciclina::cinasas CDC2-CDC28::cinasa 5 dependiente de la ciclina [COMPUESTOS QUÍMICOS Y DROGAS], Cyclin-dependent kinase 5, oxaliplatin, Marcadors tumorals, Biochemical markers, Cyclin-dependent kinase 5 (Cdk5), medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Oxaliplatin, Enzymes, Quinases dependents de ciclina, 030104 developmental biology, Oncology, nervous system, 030220 oncology & carcinogenesis, Localized disease, Prognostic and predictive biomarker, Marcadors bioquímics, Cancer research, biology.protein, Recte - Càncer, Enzims, business, prognostic and predictive biomarker, medicine.drug
Abstract: Colorectal cancer; Cyclin-dependent kinase 5 (Cdk5); Prognostic and predictive biomarker Cáncer colorrectal; Quinasa dependiente de ciclina 5 (Cdk5); Biomarcador pronóstico y predictivo Càncer colorectal; Quinasa dependent de ciclina 5 (CDK5); Biomarcador pronòstic i predictiu In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease. This work has been funded by the ISCIII grants from the Spanish Government, project numbers PI09/01334 and PI12/02228, and the Departament d’Innovació, Universitats i Empresa, Generalitat de Catalunya, project numbers 2014-SGR-1494, 2017-SGR-1705 and 2017-SGR-723. The group from Eva Martinez Balibrea is furthermore funded by the PIE16/00011 and the group from Diego Arango by the PI16/00540 and AC15/00066 grants.
Published: 2019

45. Prevalence, Clinical Characteristics, and Risk Factors for Non-recording of Alcohol Use in Hospitals across Europe: The ALCHIMIE Study

Author: Beatriz Rosón, Xavier Corbella, Pascal Perney, Arsénio Santos, Rudolf Stauber, Margus Lember, Alexander Arutyunov, Ieva Ruza, Jan Vaclavik, Luis García, Ramon Pujol, Wolgang Vogel, Jaromira Gajdová, Andrea Smrzova, Aneta Liberdová, Lubica Cibickova, Jiri Plasek, Tereza Svarcova, Riina Salupere, Mª Nieves Guillem, Joaquim Fernández-Sola, Antonio Zapatero, Rafael Monte, Rubén B. Puerta, Rocio Gamallo, Carmen Durán, Abdel Ouakli, Eric Oziol, Dominique Bastide, Patricia Tourneaire, Gerard Allard, Henry Cros, Jean-Munie Piala, Isabelle Quere, Sylvain Condouret, Ieva Ruža, Konrads Funka, Lauma Zarina, José Barata, Olga Gonsalves, Narciso Oliveira, Sergey Yakushin, Lidiya Petrovicheva, Alexander Sleptsov, Gasanov Mitkhat, Irina Marusenko, Institut d'Investigació Biomèdica de Bellvitge [Barcelone] (IDIBELL), Universitat Internacional de Catalunya, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Universidade de Coimbra [Coimbra], Medical University Graz, University of Tartu, Riga East Clinical University Hospital, Partenaires INRAE, University Hospital Olomouc, University Hospital Olomouc [Czech Republic], Hospital Universitari Germans Trias I Pujol [Badalona], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), and Université Montpellier 1 (UM1)-Université de Montpellier (UM)
Subjects: Adult, Male, medicine.medical_specialty, Multivariate analysis, Adolescent, Alcohol Drinking, Cross-sectional study, Poison control, Alcohol use disorder, Medical Records, Occupational safety and health, Young Adult, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Risk Factors, Injury prevention, Prevalence, medicine, Humans, 030212 general & internal medicine, Young adult, Aged, Aged, 80 and over, business.industry, Medical record, Age Factors, General Medicine, Middle Aged, medicine.disease, Hospitals, 3. Good health, Europe, Cross-Sectional Studies, Emergency medicine, Female, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery
Abstract: International audience; AIM: To determine the detection rates, clinical features, and risk factors for lack of registration of alcohol use in medical patients admitted in European hospitals.METHODS: A point-prevalence, cross-sectional, multicenter survey involving 2100 medical inpatients from 43 hospitals from 8 European countries. Patients were screened for current alcohol use, using standardized questionnaires. Alcohol use recording in medical records was assessed.RESULTS: Of the 2100, more than a half reported alcohol use. Significant differences were shown in the prevalence of drinking and the recording rates of alcohol use among the hospitals and countries involved. Overall, 346 patients (16%) fulfilled criteria for alcohol use disorder. Alcohol use was registered in 909 (43%) of medical records, with quantification in 143 (7%). Multivariate analysis showed that women (OR 1.49), older age patients (OR 1.23), patients from the Northern European countries (OR 4.79) and from hospitals with high local alcohol prevalence (OR 1.59) were more likely to have lack of alcohol use registration in their medical files.CONCLUSIONS: A considerable proportion of medical patients admitted in European hospitals fulfill criteria for alcohol use disorders. These patients are frequently overlooked during hospitalization and not appropriately registered in medical records. Women, older patients, and inpatients from European areas with high local alcohol use prevalence are at higher risk associated with a non-recording of alcohol use.
Published: 2016

46. Mujeres que usan drogas inyectadas y violencia: Necesidad de una respuesta integrada

Author: M. Teresa Brugal, Joan Colom, Mercè Meroño, Victoria González, Xavier Majó, Jordi Casabona, Albert Espelt, Cinta Folch Toda, [Folch C, Casabona J] Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Majó X, Colom J] Sub-direcció General de Drogodependències. Programa de Prevenció, Control i Atenció al VIH, les ITS i les Hepatitis Víriques (PCAVIHV), Agència de Salut Pública de Catalunya, Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. [Meroño M] Fundació Àmbit Prevenció, Barcelona, Spain. [González V] Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain. Servicio de Microbiología. Laboratori Clínic de la Metropolitana Nord. Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Brugal MT] Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Agència de Salut Pública de Barcelona, Barcelona, Spain. [Espelt A] Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. Agència de Salut Pública de Barcelona, Barcelona, Spain. Facultat de Ciències de la Salut de Manresa. Universitat de Vic Universitat Central de Catalunya (UVicUCC), Manresa, Spain, and Departament de Salut
Subjects: Psychiatry and Mental health, Dones - Consum de drogues, Health Care (Public Health)::Health of Specific Groups::Family Health::Violence Against Women [PUBLIC HEALTH], Violència envers les dones, personas::consumidores de drogas [DENOMINACIONES DE GRUPOS], atención a la salud (salud pública)::salud de grupos específicos::salud familiar::violencia contra la mujer [SALUD PÚBLICA], virosis::hepatitis viral humana::hepatitis C [ENFERMEDADES], Virus Diseases::Hepatitis, Viral, Human::Hepatitis C [DISEASES], Medicine (miscellaneous), Persons::Drug Users [NAMED GROUPS], Hepatitis C
Abstract: Hepatitis C; Dones; Drogues; Violència Hepatitis C; Mujeres; Drogas; Violencia Hepatitis C; Women; Drugs; Violence El objetivo de este estudio fue describir la prevalencia de violencia física y/o sexual experimentada por mujeres que usan drogas por vía inyectada (MUDVI) e identificar factores asociados. Se realizó un estudio transversal en 120 MUDVI usuarias de centros de reducción de daños mediante un cuestionario anónimo y recogida de muestras de fluido oral para estimar la prevalencia del VIH y de la hepatitis C. Los factores asociados a la presencia de violencia se analizaron mediante un modelo de regresión de Poisson con varianza robusta univariante y multivariante, obteniendo razones de prevalencia (RP) y sus intervalos de confianza al 95%. Los resultados muestran que la prevalencia de agresiones en los últimos 12 meses fue del 45,8% (42,2% agresiones físicas y 11,9% agresiones sexuales). A nivel multivariante, las variables asociadas a la presencia de violencia fueron estar sin domicilio fijo (RP=1,59; IC: 1,07-2,38), ejercer el trabajo sexual (RP=1,65; IC: 1,19-2,29), haber sufrido alguna infección de transmisión sexual (RP=1,49; IC: 1,04-2,15) y/o inyectarse drogas no de forma diaria (RP=2,29; IC: 1,49-3,54). Este estudio pone de manifiesto la importancia de establecer protocolos de detección, y derivación a la red de atención a la violencia de género, dentro de los centros de la red de atención a las drogodependencias, así como el desarrollo de estrategias multinivel que tengan en cuenta no solamente factores individuales sino también otros aspectos sociales y/o estructurales que pueden estar jugando un papel relevante a la hora de abordar este problema. The aim of this study was to describe the prevalence of physical and/ or sexual violence experienced by women who inject drugs (WWID) and identify associated factors. A cross-sectional study was conducted among 120 WWID in a network of harm reduction centres using an anonymous questionnaire. Oral fluid samples were also collected to estimate the prevalence of HIV and hepatitis C. Univariate and multivariate Poisson regression models with robust variance were performed to identify the factors associated with experiencing violence, obtaining prevalence ratios (PR) and their 95% confidence intervals. The results showed that the prevalence of violence reported by WWID in the last 12 months was 45.8% (42.2% physical and 11.9% sexual aggression). In multivariate analysis, variables associated with experiencing violence were homelessness (PR = 1.59; CI: 1.07-2.38), reporting exchanges of sex for money or drugs (PR = 1.65; CI: 1.19- 2.29), reporting a previous sexually transmitted infection (PR = 1.49; CI: 1.04-2.15) and/or injecting drugs less frequently than daily (RP = 2.29; CI: 1.49-3.54). This study highlights the importance of establishing detection protocols and systems of referral to the network of attention to women suffering violence, within the centres of the drug addiction care network, as well as the development of multilevel strategies that take into account not only individual factors but also other social and/or structural aspects that may be playing a relevant role in addressing this problem.
Published: 2020

47. Guia per al maneig dels medicaments d’alt risc: document per a la seguretat dels pacients

Author: Andreu, Àngels, Arranz-Castella, Teresa, Bravo, Carme, Cabré, Xavier, Climent, Consuelo, Duero, Marta, Estefanell, Anna, Fortes, Àfrica, Mas, Anna, Parés, Rosa M., Recha, Rebeca, Soler, Ana, Valls, Camil·la, Fernández de Gamarra Martínez, Edurne, [Andreu A] Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Arranz-Castella T, Bravo C] Hospital Comarcal de l’Alt Penedès, Vilafranca del Penedès, Spain. [Cabré X] Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Climent C] Hospital Clínic, Barcelona, Spain. [Duero M] Hospital Universitari Vall d’Hebron, Barcelona, Spain. [Estefanell, A] Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain. [Fernández de Gamarra E] Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Fortes A] Hospital Sant Pau i Santa Tecla, Tarragona, Spain. [Mas A] Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain. [Parés RM] Consorci Sanitari de l’Anoia, Igualada, Spain. [Recha R] Hospital Comarcal de Móra d’Ebre, Móra d’Ebre, Spain. [Soler A] Consorci Corporació Sanitària Parc Taulí, Sabadell, Spain. [Valls C] Consorci Hospitalari de Vic, Vic, Spain., and Departament de Salut
Subjects: Medicaments - Ús, terapéutica::farmacoterapia::errores de medicación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Errors de medicació, Therapeutics::Drug Therapy::Medication Errors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], administración de los servicios de salud::organización y administración::sistemas de medicación [ATENCIÓN DE SALUD], Health Services Administration::Organization and Administration::Medication Systems [HEALTH CARE]
Abstract: Maneig; Medicaments d'alt risc; Seguretat dels pacients Manejo; Medicamentos de alto riesgo; Seguridad de los pacientes Use; High Risk Medications; Patient safety Guia per al maneig dels MAR que permet incrementar la seguretat en l’ús d’aquests medicaments i en conseqüència oferir una atenció sanitària més segura.
Published: 2018

48. Durada del tractament antibiòtic: es pot escurçar amb seguretat

Author: Mòdol-Deltell, Josep M., Álvarez-Martins, Marlene, Giménez-Pérez, Montserrat, Equip PROA-Hospital Universitari Germans Trias i Pujol, Badalona, Spain, and Departament de Salut
Subjects: administración de los servicios de salud::administración de los servicios de salud::calidad de la atención sanitaria::revisión de utilización::revisión de la utilización de medicamentos::programas de optimización del uso de los antimicrobianos [ATENCIÓN DE SALUD], Health Services Administration::Health Services Administration::Quality of Health Care::Utilization Review::Drug Utilization Review::Antimicrobial Stewardship [HEALTH CARE], Fenómenos Fisiológicos::Fenómenos Farmacológicos y Toxicológicos::Fenómenos Farmacológicos::Resistencia a Medicamentos::Farmacorresistencia Microbiana::Farmacorresistencia Bacteriana [FENÓMENOS Y PROCESOS], Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [CHEMICALS AND DRUGS], Antibiòtics, Administración de los Servicios de Salud::Administración de los Servicios de Salud::Calidad de la Atención de Salud::Revisión de Utilización de Recursos::Revisión de la Utilización de Medicamentos::Programas de Optimización del Uso de los Antimicrobianos [ATENCIÓN DE SALUD], Microorganismes - Resistència als medicaments, Acciones y Usos Químicos::Acciones Farmacológicas::Usos Terapéuticos::Antiinfecciosos::Antibacterianos [COMPUESTOS QUÍMICOS Y DROGAS], Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance, Microbial::Drug Resistance, Bacterial [PHENOMENA AND PROCESSES], Resistència als medicaments
Abstract: Durada; Antibiòtics; Resistències Duración; Antibióticos; Resistencias Duration; Antibiotics; Resistances La necessitat de donar una solució urgent al problema de les resistències bacterianes i a la manca de nous tractaments efectius ha propiciat la creació dels programes d’optimització de l’ús d’antimicrobians (PROA). Un dels objectius d’aquests programes és promoure la durada de tractaments efectius el més curts possibles, degut al fet que l’eficàcia és màxima en el primers dies de tractament mentre que els efectes adversos (el desenvolupament de resistències i la toxicitat) i la despesa s’incrementen a mesura que aquests s’allarguen. Estem assistint a un canvi de paradigma. Hi ha suficient evidència per recomanar tractaments curts en la infecció del tracte urinari, en la pneumònia adquirida en la comunitat i en l’associada a ventilació mecànica, en la infecció intraabdominal, en l’otitis mitjana aguda i en la sinusitis aguda bacteriana. No obstant això, s’ha de tenir en compte que no són candidats a tractaments curts els pacients amb immunosupressió greu, les infeccions greus, les infeccions sense control quirúrgic del focus, les infeccions per bacteris multiresistents, els pacients sense adequada resposta inicial, les infeccions protètiques i les infeccions en localitzacions de difícil accés per als antibiòtics. En aquest Butlletí es revisen les durades recomanades per a les diferents patologies. La necesidad de dar una solución urgente al problema de las resistencias bacterianas y a la falta de nuevos tratamientos efectivos ha propiciado la creación de los programas de optimización del uso de antimicrobianos (PROA). Uno de los objetivos de estos programas es promover la duración de tratamientos efectivos lo más cortos posibles, debido a que la eficacia es máxima en el primeros días de tratamiento mientras que los efectos adversos (el desarrollo de resistencias y la toxicidad) y la gasto se incrementan a medida que estos se alargan. Estamos asistiendo a un cambio de paradigma. Hay suficiente evidencia para recomendar tratamientos cortos en la infección del tracto urinario, en la neumonía adquirida en la comunidad y en la asociada a ventilación mecánica, en la infección intraabdominal, en la otitis media aguda y en la sinusitis aguda bacteriana. Sin embargo, se debe tener en cuenta que no son candidatos a tratamientos cortos los pacientes con inmunosupresión grave, las infecciones graves, las infecciones sin control quirúrgico del foco, las infecciones por bacterias multirresistentes, los pacientes sin adecuada respuesta inicial, las infecciones protésicas y las infecciones en localizaciones de difícil acceso para los antibióticos. En este Boletín se revisan las duraciones recomendadas para las diferentes patologías The need to provide an urgent solution to the problem of bacterial resistance and the lack of effective new treatments has led to the creation of programs to optimize the use of antimicrobials (PROA). One of the objectives of these programs is to promote the duration of effective treatments as short as possible, because the efficacy is maximum in the first days of treatment while the adverse effects (the development of resistance and toxicity) and the expense are they increase as they lengthen. We are witnessing a paradigm shift. There is sufficient evidence to recommend short courses in urinary tract infection, in community-acquired pneumonia and in those associated with mechanical ventilation, in intra-abdominal infection, in acute otitis media and in acute bacterial sinusitis. However, it should be borne in mind that patients with severe immunosuppression, serious infections, infections without surgical control of the focus, infections with multiresistant bacteria, patients without adequate initial response, prosthetic infections, are not candidates for short treatments. infections in locations that are difficult to access for antibiotics. In this Bulletin the recommended durations for the different pathologies are reviewed
Published: 2018

49. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

Author: Mulligan, Nikki, Smith, Elizabeth, Hidalgo-Tenorio, Carmen, Chakhtoura, Nahida, Van Kasteren, Marjo, Fletcher, Courtney C.V., Mirochnick, Mark, Burger, David, Antinori, Andrea, Ende, Ineke van der, Faetkenheuer, Gerd, Schalkwijk, Stein, Giaquinto, Carlo, Gilleece, Yvonne, Gingelmaier, Andrea, Haberl, Annette, Hawkins, David, Ivanovic, Jelena, Kabeya, Kabamba, Lambert, John, Lyons, F., Nellen, Jeannine F J B J., Best, Brookie Manning Dugan B.M., Nicastri, Emanuelle, Rockstroh, Jürgen, Schwarze-Zander, Carolynne, Ruiter, Annemiek de, Sadiq, Tariq, van der Ven, André J A M A.J.A.M., Weizsäcker, Katharina, Wood, Chris G A C., Wyen, Christoph, Colbers, Angela P H, Wang, Jiajia, Capparelli, Edmund E.V., Moltó, José, Stek, Alice A.M., Taylor, Graham G.P., PANNA Network and the IMPAACT 1026s Study Teams, [Mulligan,N, Best,BM, Capparelli,EV] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA. [Schalkwijk,S, Colbers,A, Burger,D] Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands. [Wang,J] Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA. [Moltó,J] Fundació Lluita contra la Sida, Hospital Universitari Germans Trias I Pujol, Badalona, Spain. [Stek,AM] Maternal Child and Adolescent/Adult Center, University of Southern California School of Medicine, Los Angeles, CA, USA. [Taylor,G] Imperial College Healthcare National Health Service Trust, London, UK. [Smith,E] Maternal, Adolescent, and Pediatric Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. [Hidalgo Tenorio,C] Hospital Universitario Virgen de las Nieves Granada, Granada, Spain. [Chakhtoura,N] Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA. [van Kasteren,M] Department of Internal Medicine, St. Elisabeth Hospital, Tilburg, Netherlands. [Fletcher,CV] Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. [Mirochnick,M] Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA., Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). Overall support for the 'Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA)' network is financially supported by the 'European AIDS Treatment Network (NEAT)' under the European Commission, DG Research, 6th Framework program, contract LSHP-CT-2006-037570 and the 'Pediatric European Network for Treatment of AIDS (PENTA)' under the European Commission, DG Research, 5th Framework program, contract QLK2-CT-2000-00150 and 6th Framework program, contract LSHP-CT-2006-018865, with co-funding from Merck Sharp & Dohme Corp, Bristol Myers Squibb, Janssen Research and ViiV Healthcare., UMC St Radboud, [Mulligan, Nikki] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA, [Best, Brookie M.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA, [Capparelli, Edmund V.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA, [Schalkwijk, Stein] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands, [Colbers, Angela] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands, [Burger, David] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, Nijmegen, Netherlands, [Wang, Jiajia] Harvard Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA, [Molto, Jose] Hosp Badalona Germans Trias & Pujol, Fdn Lluita Contra Sida, Badalona, Spain, Univ Southern Calif, Maternal Child & Adolescent Adult Ctr, Sch Med, Los Angeles, CA USA, [Taylor, Graham] Imperial Coll Healthcare Natl Hlth Serv Trust, London, England, [Smith, Elizabeth] NIAID, Maternal Adolescent & Pediat Res Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA, [Tenorio, Carmen Hidalgo] Hosp Univ Virgen Nieves Granada, Granada, Spain, [Chakhtoura, Nahida] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, Bethesda, MD USA, [van Kasteren, Marjo] St Elizabeth Hosp, Dept Internal Med, Tilburg, Netherlands, [Fletcher, Courtney V.] Univ Nebraska Med Ctr, Coll Pharm, Antiviral Pharmacol Lab, Omaha, NE USA, [Mirochnick, Mark] Boston Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA, National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), 'European AIDS Treatment Network (NEAT)' under the European Commission, DG Research, 6th Framework program, 'Pediatric European Network for Treatment of AIDS (PENTA)' under the European Commission, DG Research, 5th Framework program, 6th Framework program, Merck Sharp Dohme Corp, Bristol Myers Squibb, Janssen Research, ViiV Healthcare, NATIONAL CENTER FOR RESEARCH RESOURCES, and NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Subjects: Perinatal transmission, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Postpartum Period [Medical Subject Headings], lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Etravirine, Reproductive health and childbirth, Enfuvirtide, Pharmacologie, 030226 pharmacology & pharmacy, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Pregnancy, Transplacental passage, Infant Mortality, Estudios prospectivos, Transmisión vertical de enfermedad infecciosa, Pharmacology (medical), 030212 general & internal medicine, Prospective cohort study, Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings], Darunavir, Original Research, Metas, Health Care::Population Characteristics::Health::Women's Health::Maternal Health [Medical Subject Headings], Pediatric, Cromatografía liquida, Femenino, Pharmacology and Pharmaceutical Sciences, Sangre fetal, Periodo posparto, Humanos, 3. Good health, In utero, 6.1 Pharmaceuticals, Cord blood, Combination, Health Care::Environment and Public Health::Public Health::Disease Transmission, Infectious::Infectious Disease Transmission, Vertical [Medical Subject Headings], HIV/AIDS, perinatal transmission, Límite de detección, Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings], pregnancy, Safety, Piridazinas, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyridazines [Medical Subject Headings], Infection, pharmacokinetics, medicine.drug, medicine.medical_specialty, Efficacy, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Embarazo, Clinical Trials and Supportive Activities, Anatomy::Fluids and Secretions::Body Fluids::Blood::Fetal Blood [Medical Subject Headings], Salud materna, 03 medical and health sciences, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Motivation::Goals [Medical Subject Headings], Pharmacokinetics, Clinical Research, Woman, medicine, etravirine, Dosing, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Chemistry Techniques, Analytical::Chromatography::Chromatography, Liquid [Medical Subject Headings], Pharmacology, Gynecology, business.industry, Darunavir/ritonavir, Prevention, lcsh:RM1-950, HIV, Perinatal Period - Conditions Originating in Perinatal Period, medicine.disease, Infecciones por VIH, Raltegravir, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], lcsh:Therapeutics. Pharmacology, Pharmacodynamics, Check Tags::Female [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Sensitivity and Specificity::Limit of Detection [Medical Subject Headings], 1115 Pharmacology And Pharmaceutical Sciences, business
Abstract: Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women. Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women. Intensive steady-state 12-h pharmacokinetic profiles were performed from 2nd trimester through postpartum. Etravirine was measured at two labs using validated ultra performance liquid chromatography (detection limits: 0.020 and 0.026 mcg/mL). Results: Fifteen women took etravirine 200 mg twice-daily. Etravirine AUC0-12 was higher in the 3rd trimester compared to paired postpartum data by 34% (median 8.3 vs. 5.3 mcg*h/mL, p = 0.068). Etravirine apparent oral clearance was significantly lower in the 3rd trimester of pregnancy compared to paired postpartum data by 52% (median 24 vs. 38 L/h, p = 0.025). The median ratio of cord blood to maternal plasma concentration at delivery was 0.52 (range: 0.19-4.25) and no perinatal transmission occurred. Conclusion: Etravirine apparent oral clearance is reduced and exposure increased during the third trimester of pregnancy. Based on prior dose-ranging and safety data, no dose adjustment is necessary for maternal health but the effects of etravirine in utero are unknown. Maternal health and infant outcomes should be closely monitored until further infant safety data are available. Clinical Trial registration: The IMPAACT protocol P1026s and PANNA study are registered at ClinicalTrials.gov under NCT00042289 and NCT00825929., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2016

50. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Author: Fabio Benedetti, Angelo Michele Carella, Michele Cimminiello, Elisabetta Terruzzi, Jaime Pérez De Oteiza, Kröger N, Francesca Bonifazi, Nicola Mordini, Rafael F. Duarte, Jorge Sierra, Jürgen Finke, Francesca Patriarca, Christine Wolschke, Carlos Solano, Franco Narni, Antonio M. Risitano, Domenico Pastore, Wolfgang Bethge, Francis Ayuk, Mario Petrini, Carmine Selleri, Tapani Ruutu, Giuseppe Messina, Arnon Nagler, Andreas Völp, Christelle Ferra, Marion Heinzelmann, Massimo Pini, Giuseppe Bandini, Manuel Jurado, Giuseppe Milone, Domenico Russo, Stefano Guidi, [Kröge,N, Wolschke ,C, Heinzelmann,M, Ayuk,F ] University Medical Center Hamburg-Eppendorf,Hamburg, Germany. [Finke,J] University Hospital Freiburg, Freiburg ,Germany. [Bethge,W] University Hospital Tübingen, Tübingen, Germany. [Völp,A] Psy Consult, Frankfurt, Germany. [Solano,C] Hospital Clinico Universitario, Valencia, Spain. [Pérez de Oteiza,J] Hospital Ramon y Cajal, Madrid, Spain. [Duarte,R] Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. [Ferra,C] Servicio de Hematología, Institut Català d’Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Sierra,J] Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Jurado,M] Hospital Virgen de las Nieves, Granada, Spain. [Bandini,G, Bonifaz,F] Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy. [Patriarca,F] Hematology, DISM, University Udine, Udine. Azienda Ospedaliera SS Antonio e Biagio e C. Arrigo, Alessandria, Italy. [Pini,M] Università Federico II di Napoli, Naples, Italy. [Selleri,C, Risitano,A) A.O. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy. [Messina,G] Ospedale Casa Sollievo della Sofferenza IRCCCS, San Giovanni Rotondo, Italy. [Carella,AM] Azienda Ospedaliera San Carlo, Potenza, Italy. [Cimminiello,M] Azienda Ospedaliera Careggi, Florence, Italy. [Guido,E] Ospedale Santa Croce, e Carle, Cuneo, Italy. [Mordini,N] University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy. [Russo,D] University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy. [Petrini,M] Programma di Trapianto Emopoietico Metropolitano, Azienda Policlinico-Vittorio Emanuele, Catania, Italy. [Milone,R] Policlinico G.B. Rossi, Verona, Italy. [Benedetti,F] Azienda Ospedaliera, Universitaria Ospedale, Bari, Italy. [Pastore,D] Ospedale San Gerardo, Monza, Italy. [Terruzzi,E] Policlinico Modena, Modena, Italy. [Narni,F] Università di Salerno, Salerno, Italy. [Nagler,A] Chaim Sheba Medical Center, Tel Hashomer, Ramat-Gan, Israel. [Tapani,R] Helsinki University Hospital, Helsinki., Supported by a research grant from Neovii Biotech and by the European Society for Blood and Marrow Transplantation (EBMT) as an EBMT-labeled-study of the Chronic Malignancies Working Party., Kröger, Nicolau, Solano, Carlo, Wolschke, Christine, Bandini, Giuseppe, Patriarca, Francesca, Pini, Massimo, Nagler, Arnon, Selleri, Carmine, Risitano, ANTONIO MARIA, Messina, Giuseppe, Bethge, Wolfgang, De Oteiza, Jaime Pérez, Duarte, Rafael, Carella, Angelo Michele, Cimminiello, Michele, Guidi, Stefano, Finke, Jürgen, Mordini, Nicola, Ferra, Christelle, Sierra, Jorge, Russo, Domenico, Petrini, Mario, Milone, Giuseppe, Benedetti, Fabio, Heinzelmann, Marion, Pastore, Domenico, Jurado, Manuel, Terruzzi, Elisabetta, Narni, Franco, Völp, Andrea, Ayuk, Franci, Ruutu, Tapani, and Bonifazi, Francesca
Subjects: Male, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Proportional Hazards Models [Medical Subject Headings], T-Lymphocytes, Phases of clinical research, Graft vs Host Disease, Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings], Linfocitos t, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Immunosuppressive Agent, 0302 clinical medicine, Trasplante homólogo, Estudios prospectivos, Medicine, Cumulative incidence, Prospective Studies, Prospective cohort study, Child, Transplantation, Homologou, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immune Sera::Antilymphocyte Serum [Medical Subject Headings], Acute leukemia, Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes [Medical Subject Headings], Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings], Named Groups::Persons::Age Groups::Child::Child, Preschool [Medical Subject Headings], Medicine (all), Incidence, Suero antilinfocítico, General Medicine, Middle Aged, Modelos de riesgos proporcionales, 3. Good health, Humanos, Survival Rate, 030220 oncology & carcinogenesis, Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings], Child, Preschool, Female, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Immunologic Factors::Immunosuppressive Agents [Medical Subject Headings], Immunosuppressive Agents, Human, Homologous, Adult, medicine.medical_specialty, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings], Named Groups::Persons::Age Groups::Adult::Young Adult [Medical Subject Headings], Adolescent, Enfermedad injerto contra huésped, Disease-Free Survival, 03 medical and health sciences, Young Adult, Internal medicine, Named Groups::Persons::Age Groups::Adult [Medical Subject Headings], Humans, Transplantation, Homologous, Supervivencia sin enfermedad, Preschool, Survival rate, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings], Named Groups::Persons::Age Groups::Child [Medical Subject Headings], Antilymphocyte Serum, Proportional Hazards Models, Transplantation, business.industry, Enfermedad crónica, medicine.disease, Inmunosupresores, Anti-thymocyte globulin, Surgery, Diseases::Immune System Diseases::Graft vs Host Disease [Medical Subject Headings], Prospective Studie, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Transplantation::Transplantation, Homologous [Medical Subject Headings], Graft-versus-host disease, T-Lymphocyte, Check Tags::Female [Medical Subject Headings], Chronic Disease, Proportional Hazards Model, business, 030215 immunology
Abstract: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; BACKGROUND Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling. METHODS We conducted a prospective, multicenter, open-label, randomized phase 3 study of ATG as part of a conditioning regimen. A total of 168 patients were enrolled at 27 centers. Patients were randomly assigned in a 1:1 ratio to receive ATG or not receive ATG, with stratification according to center and risk of disease. RESULTS After a median follow-up of 24 months, the cumulative incidence of chronic GVHD was 32.2% (95% confidence interval [CI], 22.1 to 46.7) in the ATG group and 68.7% (95% CI, 58.4 to 80.7) in the non-ATG group (P
Published: 2016

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

2,500 results on '"Hospital Universitari Germans Trias I Pujol [Badalona]"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources